View Filing Data

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2013	Feb. 28, 2014	Jun. 30, 2013
Document and Entity Information [Abstract]
Entity Registrant Name	Emergent BioSolutions Inc.
Entity Central Index Key	0001367644
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 366
Entity Common Stock, Shares Outstanding		36,771,588
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2013

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$ 179,338	$ 141,666
Accounts receivable	60,587	96,043
Inventories	14,643	15,161
Deferred tax assets, net	0	1,264
Income tax receivable, net	5,651	0
Prepaid expenses and other current assets	12,896	9,213
Total current assets	273,115	263,347
Property, plant and equipment, net	264,240	241,764
In-process research and development	41,800	41,800
Intangible assets, net	30,148	0
Goodwill	13,954	5,502
Deferred tax assets, net	0	11,087
Other assets	3,373	730
Total assets	626,630	564,230
Current liabilities:
Accounts payable	27,521	31,297
Accrued expenses and other current liabilities	1,252	1,488
Accrued compensation	24,615	22,726
Contingent purchase consideration, current portion	1,341	0
Income tax payable, net	0	115
Deferred tax liability, net	88	0
Long-term indebtedness, current portion	0	4,470
Deferred revenue	1,834	1,811
Total current liabilities	56,651	61,907
Contingent purchase consideraton, net of current portion	15,278	0
Long-term indebtedness, net of current portion	62,000	58,304
Deferred tax liability, net	1,419	0
Other liabilities	2,117	1,891
Total liabilities	137,465	122,102
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at December 31, 2013 and December 31, 2012, respectively	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized, 37,036,996 shares issued and 36,624,043 shares outstanding at December 31, 2013; 36,272,550 shares issued and 35,869,392 outstanding at December 31, 2012	37	36
Treasury stock, at cost, 412,953 and 403,158 common shares at December 31, 2013 and 2012, respectively	(6,119)	(5,906)
Additional paid-in capital	247,637	230,964
Accumulated other comprehensive loss	(3,465)	(4,129)
Retained earnings	251,528	220,393
Total Emergent BioSolutions Inc. stockholders' equity	489,618	441,358
Noncontrolling interest in subsidiaries	(453)	770
Total stockholders' equity	489,165	442,128
Total liabilities and stockholders' equity	$ 626,630	$ 564,230

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2013	Dec. 31, 2012
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	37,036,996	36,272,550
Common stock, shares outstanding (in shares)	36,624,043	35,869,392
Treasury stock ( in shares)	412,953	403,158

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:
Product sales	$ 257,922	$ 215,879	$ 202,409
Contracts and grants	54,823	66,009	70,975
Total revenues	312,745	281,888	273,384
Operating expenses:
Cost of product sales	62,127	46,077	42,171
Research and development	119,933	120,226	124,832
Selling, general and administrative	87,883	76,018	74,282
Impairment of in-process research and development	0	9,600	0
Income from operations	42,802	29,967	32,099
Other income (expense):
Interest income	139	134	105
Interest expense	0	(6)	0
Other income (expense), net	426	1,970	(261)
Total other income (expense)	565	2,098	(156)
Income before provision for income taxes	43,367	32,065	31,943
Provision for income taxes	13,108	13,922	15,830
Net income	30,259	18,143	16,113
Net loss attributable to noncontrolling interest	876	5,381	6,906
Net income attributable to Emergent BioSolutions Inc.	$ 31,135	$ 23,524	$ 23,019
Earnings per share - basic (in dollars per share)	$ 0.86	$ 0.65	$ 0.65
Earnings per share - diluted (in dollars per share)	$ 0.85	$ 0.65	$ 0.64
Weighted-average number of shares - basic (in shares)	36,201,283	36,080,495	35,658,907
Weighted-average number of shares - diluted (in shares)	36,747,556	36,420,662	36,206,052

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Consolidated Statements of Comprehensive Income [Abstract]
Net income attributable to Emergent BioSolutions Inc.	$ 31,135	$ 23,524	$ 23,019
Reclassification of cumulative currency translation adjustment to income, net of tax	58	0	0
Foreign currency translations, net of tax	606	(816)	(1,203)
Comprehensive income	$ 31,799	$ 22,708	$ 21,816

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:
Net income	$ 30,259	$ 18,143	$ 16,113
Adjustments to reconcile to net cash provided by operating activities:
Stock-based compensation expense	11,238	11,115	10,739
Depreciation and amortization	18,958	11,197	9,355
Deferred income taxes	13,858	3,383	20,188
Non-cash development expenses from joint venture	(347)	3,670	5,290
Change in fair value of contingent obligations	735	(3,005)	221
Impairment of in-process research and development	0	9,600	0
Impairment of long-lived assets	1,172	0	976
Excess tax benefits from stock-based compensation	(3,099)	(1,588)	(4,608)
Other	51	(40)	392
Changes in operating assets and liabilities:
Accounts receivable	35,456	(21,890)	(34,873)
Inventories	518	(500)	(1,939)
Income taxes	(7,179)	8,055	1,422
Prepaid expenses and other assets	(6,226)	(1,038)	660
Accounts payable	(551)	274	2,510
Accrued expenses and other liabilities	7	169	(95)
Accrued compensation	2,092	1,649	(3,303)
Deferred revenue	26	449	(10,863)
Net cash provided by operating activities	96,968	39,643	12,185
Cash flows from investing activities:
Purchases of property, plant and equipment	(42,021)	(53,845)	(54,026)
Proceeds from sale of assets	0	11,765	0
Proceeds from maturity of investments	0	1,966	4,250
Purchase of investments	0	0	(4,187)
Acquisition of Healthcare Protective Products Division	(25,873)	0	0
Net cash used in investing activities	(67,894)	(40,114)	(53,963)
Cash flows from financing activities:
Proceeds from borrowings on long-term indebtedness	62,000	13,547	27,522
Issuance of common stock subject to employee equity plans	6,848	761	10,026
Excess tax benefits from stock-based compensation	3,099	1,588	4,608
Principal payments on long-term indebtedness and line of credit	(62,774)	(10,227)	(15,494)
Contingent obligation payments	(348)	(1,748)	(10,000)
Purchase of treasury stock	(213)	(5,906)	0
Restricted cash deposit	0	220	(3)
Net cash provided by (used in) financing activities	8,612	(1,765)	16,659
Effect of exchange rate changes on cash and cash equivalents	(14)	1	1
Net increase (decrease) in cash and cash equivalents	37,672	(2,235)	(25,118)
Cash and cash equivalents at beginning of year	141,666	143,901	169,019
Cash and cash equivalents at end of year	179,338	141,666	143,901
Supplemental disclosure of cash flow information:
Cash paid during the year for interest	2,055	2,137	1,740
Cash paid during the year for income taxes	6,331	6,537	4,280
Supplemental information on non-cash investing and financing activities:
Purchases of property, plant and equipment unpaid at year end	$ 2,755	$ 5,612	$ 13,509

Consolidated Statement of Changes in Stockholders' Equity - USD ($) $ in Thousands	$0.001 Par Value Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Loss [Member]	Noncontrolling Interest in Subsidiary [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2010	$ 35	$ 197,689	$ 0	$ (2,110)	$ 4,097	$ 173,850	$ 373,561
Balance (in shares) at Dec. 31, 2010	35,011,423		0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee equity award plans activity	$ 1	22,965		0	0	0	22,966
Employee equity award plans activity (in shares)	991,275
Non-cash development expenses from joint venture					5,290	0	5,290
Net loss attributable to noncontrolling interest					(6,906)	0	(6,906)
Net income					0	23,019	23,019
Foreign currency translations, net of tax				(1,203)	0	0	(1,203)
Balance at Dec. 31, 2011	$ 36	220,654	$ 0	(3,313)	2,481	196,869	416,727
Balance (in shares) at Dec. 31, 2011	36,002,698		0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee equity award plans activity	$ 0	10,310		0	0	0	10,310
Employee equity award plans activity (in shares)	269,852
Non-cash development expenses from joint venture				0	3,670	0	3,670
Net loss attributable to noncontrolling interest				0	(5,381)	0	(5,381)
Treasury stock			$ (5,906)	0	0		(5,906)
Treasury stock (in shares)			(403,158)
Net income				0	0	23,524	23,524
Foreign currency translations, net of tax				(816)	0	0	(816)
Balance at Dec. 31, 2012	$ 36	230,964	$ (5,906)	(4,129)	770	220,393	$ 442,128
Balance (in shares) at Dec. 31, 2012	36,272,550		(403,158)				35,869,392
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee equity award plans activity	$ 1	16,673		0	0	0	$ 16,674
Employee equity award plans activity (in shares)	764,446
Non-cash development expenses from joint venture				0	(347)	0	(347)
Net loss attributable to noncontrolling interest				0	(876)	0	(876)
Treasury stock			$ (213)	0	0		(213)
Treasury stock (in shares)			(9,795)
Net income				0	0	31,135	31,135
Foreign currency translations, net of tax				664	0	0	664
Balance at Dec. 31, 2013	$ 37	$ 247,637	$ (6,119)	$ (3,465)	$ (453)	$ 251,528	$ 489,165
Balance (in shares) at Dec. 31, 2013	37,036,996		(412,953)				36,624,043

Nature of the business and organization	12 Months Ended
Nature of the business and organization	Dec. 31, 2013
Nature of the business and organization [Abstract]
Nature of the business and organization	1. Nature of the business and organization Emergent BioSolutions Inc. (the "Company" or "Emergent") is a specialty pharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments for use in addressing medical needs and emerging health threats. The Company is developing products to be offered both to biodefense and commercial markets. The Company commenced operations as BioPort Corporation ("BioPort") in September 1998 through an acquisition from the Michigan Biologic Products Institute; which includes acquired rights to the marketed product BioThrax, vaccine manufacturing facilities at a multi-building campus on approximately 12.5 acres in Lansing, Michigan and vaccine development and production know-how. In December 2001, the U.S. Food and Drug Administration ("FDA") approved a supplement to the Company's manufacturing facility license for the manufacture of BioThrax at the renovated facilities. In June 2004, the Company completed a corporate reorganization ("Reorganization"). As a result of the Reorganization, BioPort became a wholly owned subsidiary of the Company. The Company subsequently renamed and converted this subsidiary to Emergent Biodefense Operations Lansing LLC ("Emergent Biodefense Operations"). The Company acquired a portion of its portfolio of vaccine and therapeutic product candidates through an acquisition of Microscience Limited ("Microscience") in a share exchange in June 2005, and acquisitions of substantially all of the assets, for cash, of Antex Biologics Inc. ("Antex") in May 2003 and ViVacs GmbH, Germany ("ViVacs") in July 2006. The Company renamed Microscience as Emergent Product Development UK Limited. The assets acquired from Antex are held in an entity incorporated as Emergent Product Development Gaithersburg Inc., and the assets acquired from ViVacs are held in an entity incorporated as Emergent Product Development Germany GmbH. On October 28, 2010, the Company acquired Trubion Pharmaceuticals, Inc. ("Trubion") for cash, equity and contingent value rights. Concurrent with the acquisition, the Company converted Trubion to Emergent Product Development Seattle, LLC. In August 2013, the Company acquired substantially all of the assets of the Health Protective Products Division ("HPPD") of Bracco Diagnostics Inc. ("Bracco") for cash along with contingent purchase consideration obligations.

Summary of significant accounting policies

12 Months Ended

Dec. 31, 2013

Summary of significant accounting policies [Abstract]

Summary of significant accounting policies

2. Summary of significant accounting policies

Basis of presentation and consolidation

The accompanying consolidated financial statements include the accounts of Emergent and its wholly-owned and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. For investments in variable interest entities, the Company consolidates when it is determined to be the primary beneficiary.

Use of estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents

Cash equivalents are highly liquid investments with a maturity of 90 days or less at the date of purchase and consist of time deposits and investments in money market funds with commercial banks and financial institutions. Also, the Company maintains cash balances with financial institutions in excess of insured limits. The Company does not anticipate any losses with such cash balances.

Fair value of measurements

The Company measures and records cash equivalents and investment securities considered available-for-sale at fair value in the accompanying financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value include:

Level 1 —

Observable inputs for identical assets or liabilities such as quoted prices in active markets;

Level 2 —

Inputs other than quoted prices in active markets that are either directly or indirectly observable; and

Level 3 —

Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.

The carrying amounts of the Company's short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable, approximate their fair values due to their short maturities. The fair value of the Company's long-term indebtedness is estimated based on the quoted prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities.

Significant customers and accounts receivable

For the years ended December 31, 2013, 2012 and 2011, the Company's primary customer was the U.S. Department of Health and Human Services ("HHS"). For the years ended December 31, 2013, 2012 and 2011, revenues from HHS and HHS agencies comprised 95.5%, 97.9% and 91.3%, respectively, of total revenues and are included in the Company's Biodefense segment. As of December 31, 2013 and 2012, the Company's receivable balances were comprised of 96.2% and 99.9%, respectively, from this customer. Unbilled accounts receivable, included in accounts receivable, as of December 31, 2013 and 2012 were $14.8 million and $19.9 million, respectively, relates to various service contracts for which work has been performed, though invoicing has not yet occurred. Substantially all of the unbilled receivables are expected to be billed and collected within the next 12 months. Accounts receivable are stated at invoice amounts and consist primarily of amounts due from the U.S. government and collaborative partners as well as amounts due under reimbursement contracts with other government entities and non-government and philanthropic organizations. If necessary, the Company records a provision for doubtful receivables to allow for any amounts which may be unrecoverable. This provision is based upon an analysis of the Company's prior collection experience, customer creditworthiness and current economic trends. As of December 31, 2013 and 2012, an allowance for doubtful accounts was not recorded as the collection history from the Company's customers indicated that collection was probable.

Concentrations of credit risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and investments and accounts receivable. The Company places its cash and cash equivalents and investments with high quality financial institutions. Management believes that the financial risks associated with its cash and cash equivalents and investments are minimal. Because accounts receivable consist primarily of amounts due from the U.S. government for product sales and from government agencies under government grants and development contracts, management deems there to be minimal credit risk.

Inventories

Inventories are stated at the lower of cost or market, with cost being determined using a standard cost method, which approximates average cost. Average cost consists primarily of material, labor and manufacturing overhead expenses and includes the services and products of third party suppliers. The Company analyzes its inventory levels quarterly and writes down, in the applicable period, inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected customer demand. The Company also writes off in the applicable period the costs related to expired inventory.

Property, plant and equipment

Property, plant and equipment are stated at cost. Depreciation is computed using the straight-line method over the following estimated useful lives:

Buildings	31-39 years
Building improvements	10-39 years
Furniture and equipment	3-15 years
Software	Lesser of 3-5 years or product life
Leasehold improvements	Lesser of the asset life or lease term

Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.

Income taxes

Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and research and development tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled.

The Company's ability to realize deferred tax assets depends upon future taxable income as well as the limitations discussed below. For financial reporting purposes, a deferred tax asset must be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized prior to expiration. The Company considers future taxable income and ongoing tax planning strategies in assessing the need for valuation allowances. In general, if the Company determines that it is more likely than not to realize more than the recorded amounts of net deferred tax assets in the future, the Company will reverse all or a portion of the valuation allowance established against its deferred tax assets, resulting in a decrease to the provision for income taxes in the period in which the determination is made. Likewise, if the Company determines that it is not more likely than not to realize all or part of the net deferred tax asset in the future, the Company will establish a valuation allowance against deferred tax assets, with an offsetting increase to the provision for income taxes, in the period in which the determination is made.

Under sections 382 and 383 of the Internal Revenue Code, if an ownership change occurs with respect to a "loss corporation", as defined, there are annual limitations on the amount of net operating losses and deductions that are available. The Company believes the use of net operating losses and research and development tax credits acquired in the Trubion acquisition will not be significantly limited. Due to the acquisition of Microscience in 2005 and the Company's initial public offering, the Company believes the use of the operating losses incurred prior to 2005 will be significantly limited.

Revenue recognition

The Company recognizes revenues from product sales if four basic criteria have been met:



there is persuasive evidence of an arrangement;



delivery has occurred or title has passed to the Company's customer;



the fee is fixed or determinable; and



collectability is reasonably assured.

All revenues from product sales are recorded net of applicable allowances for sales returns, rebates, special promotional programs, and discounts. For arrangements where the risk of loss has not passed to the customer, the Company defers the recognition of revenue until such time that risk of loss has passed to the customer. Also, the cost of revenue associated with amounts recorded as deferred revenue is recorded in inventory until such time as risk of loss has passed to the customer.

Under previous contracts with HHS, the Company invoiced HHS and recognized the related revenues upon delivery of the product to the government carrier, at which time title to the product passed to HHS. Effective September 30, 2011, the Company has a contract from the Centers for Disease Control and Prevention ("CDC"), an operating division of HHS, to supply up to 44.75 million doses of BioThrax over a five year period. Under the Company's contract from the CDC, the Company invoices the CDC and recognizes the related revenue upon acceptance by the government at delivery site, at which time title to the product passes to the CDC. In addition, the Company has generated sales under its indefinte delivery/indefinete quantity contract with the U.S. government and recogonizes revenue upon delivery.

Collaborative research and development agreements can provide for one or more of upfront license fees, research payments, and milestone payments. Agreements with multiple components ("deliverables" or "items") are evaluated to determine if the deliverables can be divided into more than one unit of accounting. An item can generally be considered a separate unit of accounting if both of the following criteria are met: (1) the delivered item(s) has value to the customer on a stand-alone basis; (2) if the arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially in control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on the relative selling price of each deliverable. The Company deems service to have been rendered if no continuing obligation exists on the part of the Company.

Revenue associated with non-refundable upfront license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting is deferred and recognized as revenue either on a straight-line basis over the Company's continued involvement in the research and development process or based on the proportional performance of the Company's expected future obligation under the contract. Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved, and the milestone payments are due and collectible. If not deemed substantive, the Company would recognize such milestone as revenue on a straight-line basis over the remaining expected term of continued involvement in the research and development process.

Milestones are considered substantive if all of the following conditions are met; (1) the milestone is non-refundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended. Payments received in advance of work performed are recorded as deferred revenue.

The Company generates contract and grant revenue from cost-plus-fee contracts. Revenues on reimbursable contracts are recognized as costs are incurred, generally based on allowable costs incurred during the period, plus any recognizable earned fee. The Company considers fixed fees under cost-plus-fee contracts to be earned in proportion to the allowable costs incurred in performance of the contract. The Company analyzes costs for contracts and reimbursable grants to ensure reporting of revenues gross versus net is appropriate. For each of the three years in the period ended December 31, 2013, the costs incurred under the contracts and grants approximated the revenue earned.

The Company analyzes its multiple element revenue-generating arrangements to determine whether the elements can be separated and accounted for individually as separate units of accounting. An item can generally be considered a separate unit of accounting if both of the following criteria are met: the delivered item(s) has value to the customer on a stand-alone basis and if the arrangement includes a general right of return and delivery or performance of the undelivered item(s) is considered probable and substantially in the control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on the unit's selling price and is recognized in full when the criteria are met. The Company deems services to be rendered if no continuing obligation exists on the part of the Company.

The Company's contract with the Biomedical Advanced Research and Development Authority ("BARDA") to establish a Center for Innovation in Advanced Development and Manufacturing ("CIADM") is a service arrangement that includes multiple elements. The CIADM contract requires the Company to provide a flexible infrastructure to supply medical countermeasures to the U.S. government over the contract period and includes such items as construction and facility design, workforce development and licensure of a pandemic flu vaccine. Since none of the individual elements by themselves satisfy the purpose of the contract, the Company has concluded that the CIADM contract elements cannot be separated as they do not have stand-alone value to the U.S. government. Therefore, the Company has concluded that there is a single unit of accounting associated with the CIADM contract. The Company recognizes revenue under the CIADM contract on a straight-line basis, based upon its estimate of the total payments to be received under the contract. The Company analyzes the estimated payments to be received on a quarterly basis to determine if an adjustment to revenue is required. Changes in estimates attributed to modifications in the estimate of total payments to be received are recorded prospectively

Contingent purchase consideration obligations

In accordance with the terms of the Company's August 2013 acquisition of HPPD, the Company may be required to make additional payments on a quarterly basis to Bracco, based on achievement of certain net sales thresholds of RSDL through 2028. The Company records this obligation at fair value. Contingent purchase consideration is based on a percentage of future net RSDL sales. The fair value model used to calculate this obligation is based on the income approach (a discounted cash flow model) that has been risk adjusted based on the probability of achievement of net sales.

The inputs the Company uses for determining the fair value of the contingent purchase consideration are Level 3 fair value measurements. The Company re-evaluates the fair value of the contingent purchase consideration obligation on a quarterly basis. Changes in the fair value can result from adjustments to the discount rates and updates in the assumed timing of or achievement of net sales. Any future increase in the fair value of the contingent purchase consideration obligation is based on an increased likelihood that the underlying net sales will be achieved and the associated payment or payments which will therefore become due and payable. These increases in the fair value of the contingent purchase consideration obligation will result in a charge to cost of product sales in the period in which the increase is determined. Similarly, any future decrease in the fair value of the contingent purchase consideration obligation will result in a reduction in cost of product sales.

Contingent value rights

The Company records contingent value right ("CVR") obligations at fair value. Obligations generally become due and payable only upon achievement of certain developmental, regulatory or commercial milestones. The fair value model used for the CVR obligations are based on a discounted cash flow model that has been risk adjusted based on the probability of achievement of the milestones.

The Company believes that the inputs it uses for determining the fair value of the CVR obligations are Level 3 fair value measurements. The Company re-evaluates the fair value on a quarterly basis. Changes in the fair value of the CVR obligations can result from adjustments to the discount rates, updates in the assumed timing of achievement of any development milestones or changes in the probability of certain events and changes in the assumed probability associated with approval. Any future increase in the fair value of the CVR obligations, based on an increased likelihood that the underlying milestones will be achieved and the associated payment or payments will therefore become due and payable, will result in a charge to research and development expense in the period in which the increase is determined. Similarly, any future decrease in the fair value of the CVR obligations will result in a reduction in research and development expense.

Intangible assets and acquired in-process research and development

Intangible assets represent the fair value assigned to products and medical devices that the Company acquired. The value assigned to intangible assets is determined by estimating the revenues and costs from these products and medical devices, and discounting the net cash flows to present value. The revenue and cost projections used to value intangibles assets are, as applicable, reduced based on the probability of achieving sales and cost forecasts.

Acquired in-process research and development ("IPR&D") represents the fair value assigned to research and development assets that the Company acquires that have not been completed at the date of acquisition. The value assigned to acquired IPR&D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value. The revenue and cost projections used to value acquired IPR&D are, as applicable, reduced based on the probability of developing a new drug.

Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology, and the nature and expected timing of new product introductions by us and our competitors. The resulting net cash flows from such projects are based on management's estimates of cost of sales, operating expenses, and income taxes from such projects. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections described above. The Company determines the fair values of these assets as of the acquisition date using discounted cash flow models. These models require the use of significant estimates and assumptions, including but not limited to:

§	estimating the timing of and expected costs to complete the in-process projects;

§	projecting the likelihood and timing of regulatory approvals;

§	estimating future cash flows from product sales resulting from completed products and in-process projects; and

§	developing appropriate discount rates and probability rates by project.

The Company believes the fair values assigned to acquired intangible and IPR&D assets are based upon reasonable estimates and assumptions given available facts and circumstances as of the acquisition date. If these assets are not successful or successfully developed, sales and profitability will be adversely affected in future periods, and as a result, the value of the assets may become impaired.

The Company amortizes intangible assets based on the estimated useful life.

Intangible assets are tested for impairment whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. The Company assesses IPR&D assets for impairment on an annual basis or more frequently if indicators of impairment are present. The Company's annual assessment includes a comparison of the fair value of IPR&D assets to existing carrying value, and recognizes an impairment when the carrying value is greater than the determined fair value. The Company believes that the assumptions used in valuing the intangible and IPR&D assets are reasonable and are based upon its best estimate of likely outcomes of sales and clinical development. The underlying assumptions and estimates used to value these assets are subject to change in the future, and actual results may differ significantly from the assumptions and estimates. The Company has selected October 1^st as its annual impairment test date for indefinite-lived intangible assets.

Goodwill

The Company assesses the carrying value of goodwill on an annual basis, or whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable, to determine whether any impairment in this asset may exist and, if so, the extent of such impairment. The provisions of the relevant accounting guidance require that the Company perform a two-step impairment test. In the first step, the Company compares the fair value of its reporting unit to the carrying value of the reporting unit. If the carrying value of the reporting unit exceeds the fair value of the reporting unit, then the second step of the impairment test is performed in order to determine the implied fair value of the reporting unit's goodwill. If the carrying value of the reporting unit's goodwill exceeds its implied fair value, an impairment loss equal to the difference is recorded and charged to general and administrative expense. The Company calculates the fair value of the reporting unit utilizing the income approach. The income approach utilizes a discounted cash flow model, using a discount rate based on the Company's estimated weighted average cost of capital.The Company evaluates goodwill using the qualitative assessment method which permits companies to qualitatively assess whether it is more-likely-than-not that the fair value of a reporting unit is less than its carrying amount. The Company considers developments in its operations, the industry in which it operates and overall macroeconomic factors that could have affected the fair value of the reporting unit since the date of the most recent calculation of a reporting unit's fair value when evaluating whether to perform a quantitative evaluation.

The determination of the fair value of a reporting unit is judgmental in nature and involves the use of significant estimates and assumptions. The estimates and assumptions used in calculating fair value include identifying future cash flows, which requires that the Company makes a number of critical legal, economic, market and business assumptions that reflect best estimates as of the testing date. The Company's assumptions and estimates may differ significantly from actual results, or circumstances could change that would cause the Company to conclude that an impairment now exists or that it previously understated the extent of impairment. The Company selected October 1^st as its annual impairment test date.

Impairment of long-lived assets

The Company assesses the recoverability of its long-lived assets for which an indicator of impairment exists by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If the Company concludes that the carrying value will not be recovered, the Company measures the amount of such impairment by comparing the fair value to the carrying value.

Research and development

Research and development costs are expensed as incurred. Research and development costs primarily consist of salaries and fees paid to outside service providers and the costs of materials used in clinical trials and research and development. Other research and development expenses include fees paid to consultants, materials and related expenses for personnel and facility expenses.

Comprehensive income

Comprehensive income is comprised of net income and other changes in equity that are excluded from net income. The Company includes translation gains and losses incurred when converting its subsidiaries' financial statements from their functional currency to the U.S. dollar in accumulated other comprehensive income.

Foreign currencies

The local currency is the functional currency for the Company's foreign subsidiaries and, as such, assets and liabilities are translated into U.S. dollars at year-end exchange rates. Income and expense items are translated at average exchange rates during the year. Translation adjustments resulting from this process are charged or credited to other comprehensive income.

Capitalized interest

The Company capitalizes interest based on the cost of major ongoing capital projects which have not yet been placed in service. For the years ended December 31, 2013, 2012 and 2011, the Company incurred interest of $2.0 million, $2.2 million and $1.7 million, respectively. Of these amounts, the Company capitalized $2.0 million, $2.2 million and $1.7 million, respectively.

Certain risks and uncertainties

The Company has derived substantially all of its revenue from sales of BioThrax under contracts with the U.S. government. The Company's CDC contract does not necessarily increase the likelihood that it will secure future comparable contracts with the U.S. government. The Company expects that a significant portion of the business that it will seek in the near future, in particular for BioThrax, will be under government contracts that present a number of risks that are not typically present in the commercial contracting process. U.S. government contracts for BioThrax are subject to unilateral termination or modification by the government. The Company may fail to achieve significant sales of BioThrax to customers in addition to the U.S. government, which would harm its growth opportunities. The Company may not be able to sustain or increase profitability. The Company may not be able to manufacture BioThrax consistently in accordance with FDA specifications.

Earnings per share

Basic net income per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net income by the weighted average number of shares outstanding for the period. Diluted net income per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock.

Accounting for stock-based compensation

The Company has two stock-based employee compensation plans, the Second Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan (the "2006 Plan") and the Emergent BioSolutions Employee Stock Option Plan (the "2004 Plan" and together with the 2006 Plan, the "Emergent Plans"). The Company has granted options to purchase shares of common stock under the Emergent Plans and has granted restricted stock units under the 2006 Plan. The Emergent Plans have both incentive and non-qualified stock option features. The Company no longer grants equity awards under the 2004 Plan.

On May 17, 2012, the Company's shareholders approved amendments to the 2006 Plan, which increased the number of shares of common stock available for issuance under plan awards by 2,500,000. As of December 31, 2013, an aggregate of 11,178,826 shares of common stock were authorized for issuance under the 2006 Plan, of which a total of 2,387,463 shares of common stock remain available for future awards to be made to plan participants. As part of the May 2012 amendment, awards of restricted stock units after May 17, 2012 are counted against the maximum aggregate number of shares of common stock available for issuance under the 2006 Plan as 1.86 shares of common stock for every one restricted stock unit granted. The maximum number of shares subject to awards that may be granted per year under the 2006 Plan to a single participant is 287,700. The exercise price of each option must be not less than 100% of the fair market value of the shares underlying such option on the date of grant. Awards granted under the 2006 Plan have a contractual life of no more than 10 years. The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Emergent Plans are determined by the compensation committee of the Company's board of directors, which administers the Emergent Plans. Each equity award granted under the Emergent Plans vests as specified in the relevant agreement with the award recipient and no option can be exercised after ten years from the date of grant.

The Company determines the fair value of restricted stock units using the closing market price of the Company's common stock on the day prior to the date of grant. The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. The fair value of each option is estimated on the date of grant. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company's methodology for developing each of the assumptions used:

	Year Ended December 31,
		2013	2012	2011
Expected dividend yield		0%	0%	0%
Expected volatility		39-49%	41-52%	60%
Risk-free interest rate		0.32-0.70%	0.36-0.54%	0.35-1.04%
Expected average life of options		4.4 years	3.4 years	3.4 years



Expected dividend yield — the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.



Expected volatility — a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. The Company analyzed its own historical volatility to estimate expected volatility over the same period as the expected average life of the options.



Risk-free interest rate — the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date on which the option is granted.



Expected average life of options — the period of time that options granted are expected to remain outstanding, based primarily on the Company's expectation of optionee exercise behavior subsequent to vesting of options.

Acquisition of Healthcare Protective Products Division

12 Months Ended

Dec. 31, 2013

Acquisition of Healthcare Protective Products Division [Abstract]

Acquisition of Healthcare Protective Products Division

3. Acquisition of Healthcare Protective Products Division

On August 1, 2013, the Company acquired substantially all of the assets of the HPPD, a division of Bracco, for approximately $25.9 million in cash along with contingent purchase consideration obligations to Bracco. The assets acquired in this acquisition include HPPD's product, RSDL, and a majority of the customer and distributor agreements associated with RSDL along with approximately $1.5 million of manufacturing equipment. The acquisition diversifies the Biodefense segment by adding product sales from RSDL.

The contingent purchase consideration obligation is based on a percentage of RSDL net sales, ranging from 0-10%, for the period August 1, 2013 through July 31, 2028. At August 1, 2013, the contingent purchase consideration obligation was recorded at a fair value of $16.2 million. The Level 3 fair value of this obligation is based on management's assessment of the potential future realization of the contingent purchase consideration payments. This assessment is based on inputs that have no observable market. The obligation is measured using the income approach (a discounted cash flow model).

The total purchase price is summarized below:

(in thousands)
Amount of cash paid to Bracco Diagnostics Inc.	$	25,873
Fair value of contigent purchase consideration		16,232
Total purchase price	$	42,105

The table below summarizes the allocation of the purchase price based upon fair values of assets acquired and liabilities assumed at August 1, 2013.

(in thousands)
Acquired intangible assets		32,099
Goodwill		8,452
Acquired equipment		1,543
Other		11
Total purchase price	$	42,105

A substantial portion of the assets acquired from Bracco consisted of intangible assets associated with the RSDL product. As of the date of acquisition, the Company has recorded intangible assets of approximately $28.6 million related to RSDL, which is being amortized over 8 years, and $3.5 million related to a manufacturing agreement with Bracco, which is being amortized over 3 years. For the year ended December 31, 2013, the Company recorded $2.0 million in amortization for intangible assets, which have been recorded in cost of product sales within the Company's Biodefense segment. The weighted average amortization period for the intangible assets is 89 months.

Intangible assets consist of the following:

(in thousands)	RSDL			Manufacturing Agreement			Total
Cost Basis
Balance at December 31, 2012	$	–		$	–		$	–
Additions		28,621			3,478			32,099
Balance at December 31, 2013	$	28,621		$	3,478		$	32,099

Accumulated Amortization
Balance at December 31, 2012	$	–		$	–		$	–
Amortization		(1,468	)		(483	)		(1,951	)
Balance at December 31, 2013	$	(1,468	)	$	(483	)	$	(1,951	)

Net book value at December 31, 2013	$	27,153		$	2,995		$	30,148

Future amortization expense as of December 31, 2013 is as follows:

(in thousands)
2014	$	4,737
2015		4,737
2016		4,255
2017		3,587
2018 and beyond		12,832
Total remaining amortization	$	30,148

The Company recorded approximately $8.5 million in goodwill related to the HPPD acquisition representing the purchase price paid in the acquisition in excess of the fair value of the tangible and intangible assets acquired. This goodwill is included in the Company's biodefense segment. None of the goodwill generated from the HPPD acquisition is expected to be deductible for tax purposes.

For the year ended December 31, 2013, $11.2 million of revenue and $1.9 million of revenue and net income, respectively, has been included in the Company's statements of operations.

The Company incurred transaction costs related to the HPPD acquisition of approximately $600,000 for the year ended December 31, 2013, which have been recorded in selling, general and administrative expenses within the Company's Biodefense segment.

The Company has determined the historical results of HPPD were not significant to the Company's results of operations, and as such no proforma disclosures have been presented.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6910749&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=25497992&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7488404&loc=d3e6996-128479

+ Details

Fair value measurements

12 Months Ended

Dec. 31, 2013

Fair value measurements [Abstract]

Fair value measurements

4. Fair value measurements

The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

	At December 31, 2013
(in thousands)		Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)		$	37,701	$	-	$	-	$	37,701
Total assets		$	37,701	$	-	$	-	$	37,701

Liabilities:
Contingent purchase consideration		$	-	$	-	$	16,619	$	16,619
Total liabilities		$	-	$	-	$	16,619	$	16,619

	At December 31, 2012
(in thousands)		Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)		$	42,720	$	-	$	-	$	42,720
Total assets		$	42,720	$	-	$	-	$	42,720

(1) Included in cash and cash equivalents in accompanying consolidated balance sheets.

As of December 31, 2013 and 2012, the Company did not have any transfers between Level 1 and Level 2 assets or liabilities.

The fair value of contingent purchase consideration obligations are based on management's assessment of changes as a result of adjustments to the discount rates and updates in the assumed and actual achievement of net sales for RSDL, which are inputs that have no observable market (Level 3). For the year ended December 31, 2013, the contingent purchase consideration obligation increased by $735,000 primarily due to an adjustment to the actual and expected timing of RSDL sales. The adjustment to fair value is classified in the Company's statement of operations as cost of product sales within the Company's Biodefense segment.

The fair value of CVR obligations is based on management's assessment of certain development and collaboration milestones, which are inputs that have no observable market (Level 3). The obligation is measured using a discounted cash flow model. As of December 31, 2013 and 2012, respectively, the Company had no CVR obligations. For the year ended December 31, 2012, the Company recorded a decrease in the CVR obligations of $3.0 million due to Pfizer Inc. ("Pfizer") ceasing development of programs related to the CVR milestones and made a $1.7 million CVR payment under the Company's agreement with Abbott Laboratories ("Abbott"). For the year ended December 31, 2011, the Company recorded an increase of $221,000 in the value for the CVRs, due to an adjustment to the discount rates along with an update to the probability and estimated timing of achievement for certain development milestones, and made a $10.0 million CVR payment under the Abbott agreement. The adjustments to fair value are classified in the Company's statement of operations as research and development expense within the Company's Biosciences segment

The following table is a reconciliation of the beginning and ending balance of the liabilities measured at fair value using significant unobservable inputs (Level 3) during the years ended December 31, 2013 and 2012.

(in thousands)
Balance at December 31, 2011	$	4,753
Expense (income) included in earnings		(3,005	)
Settlements		(1,748	)
Purchases, sales and issuances		-
Transfers in/(out) of Level 3		-
Balance at December 31, 2012	$	-
Expense (income) included in earnings		735
Settlements		(348	)
Purchases, sales and issuances		16,232
Transfers in/(out) of Level 3		-
Balance at December 31, 2013	$	16,619

Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis, as documented above, from those measured at fair value on a nonrecurring basis. For the year ended December 31, 2013, some of the Company's equipment was measured at fair value on a non-recurring basis (see Note 7), which is categorized as a Level 3 fair value measurement. During the year ended December 31, 2012, the Company's SBI-087 IPR&D asset was measured at fair value on a nonrecurring basis (see Note 8), which is categorized as a Level 3 fair value measurement. As of December 31, 2013 and 2012, the Company had no other assets or liabilities that were measured at fair value on a nonrecurring basis.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Accounts receivable

12 Months Ended

Dec. 31, 2013

Accounts receivable [Abstract]

Accounts receivable

5. Accounts receivable

Accounts receivable consist of the following:

	December 31,
(in thousands)	2013			2012
Billed		$	45,757		$	76,155
Unbilled			14,830			19,888
Total		$	60,587		$	96,043

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

Inventories

12 Months Ended

Dec. 31, 2013

Inventories [Abstract]

Inventories

6. Inventories

Inventories consist of the following:

	December 31,
(in thousands)	2013		2012
Raw materials and supplies	$	2,656	$	2,733
Work-in-process		9,819		9,813
Finished goods		2,168		2,615
Total inventories	$	14,643	$	15,161

Property, plant and equipment

12 Months Ended

Dec. 31, 2013

Property, plant and equipment [Abstract]

Property, plant and equipment

7. Property, plant and equipment

Property, plant and equipment consist of the following:

	December 31,
(in thousands)	2013			2012
Land and improvements	$	10,605		$	4,839
Buildings, building improvements and leasehold improvements		83,823			66,953
Furniture and equipment		107,006			91,772
Software		21,832			15,691
Construction-in-progress		98,345			105,452
		321,611			284,707
Less: Accumulated depreciation and amortization		(57,371	)		(42,943	)
Total property, plant and equipment, net	$	264,240		$	241,764

For the years ended December 31, 2013 and 2012, construction-in-progress included costs related to Building 55, the Company's large-scale manufacturing facility, for which the Company is in the process of receiving regulatory approval.

During the year ended December 31, 2013, the Company recorded an impairment related to idle equipment of $1.2 million. The fair value of the asset group was determined via observable prices for similar equipment along with the estimated prices for scrap (salvage value). The impairment is classified in the Company's statements of operations as selling, general and administrative expense with in the Company's Biodefense segment. The impairment reflects management's assessment of the estimated recoverability of the equipment.

Depreciation and amoritization expense was $19.0 million, $11.2 million and $9.4 million for the years ended December 31, 2013, 2012 and 2011, respectively. The increase in depreciation expense as compared to December 31, 2012 was primarily due to the Company's Baltimore facility being placed-in-service in December 2012. As of December 31, 2013, 2012 and 2011 there was no unamortized internal use software-cost.

In-process research and development and goodwill	12 Months Ended
In-process research and development and goodwill	Dec. 31, 2013
In-process research and development and goodwill [Abstract]
In-process research and development and goodwill	8. In-process research and development and goodwill The Company completed its annual impairment assessments for its IPR&D asset and goodwill as of October 1, 2013 and 2012, respectively, and determined that the fair value of the IPR&D asset and goodwill was in excess of carrying value. The Company has determined its IPR&D assets and $5.5 million of goodwill is included in the Biosciences therapeutics reporting unit, a component of the Biosciences business segment. The remainder of goodwill, $8.5 million, is related to the HPPD acquisition and is included in the Company's Biodefense segment. The Company performed a quantitative assessment of goodwill associated with the Bioscience segment and a qualitative assesment of goodwill associated with the Biodefense segment. During the year ended December 31, 2012, Pfizer Inc. ("Pfizer") terminated its development programs with respect to the Company's SBI-087 product candidate. The Company considered this termination a potential indicator of impairment of the related SBI-087 IPR&D asset, and assessed the fair value of this asset. As part of the assessment, the Company considered the impact of Pfizer's decision, along with the Company's decision to no longer pursue further development of this asset due to reduced overall probability of success and increased development costs for the product candidate. As a result, the Company recorded an impairment charge of $9.6 million during the year ended December 31, 2012, which represented the entire carrying value of the SBI-087 IPR&D asset. This charge is classified in the Company's statement of operations as impairment of in-process research and development, within the Company's Biosciences segment. As a result of the impairment of the SBI-087 IPR&D asset, the Company also performed an analysis of the Biosciences therapeutic reporting unit, which contains all goodwill reported on the Company's consolidated balance sheets as of December 31, 2012. Based on the analysis, the Company concluded that goodwill was not more likely than not impaired and therefore an interim impairment analysis was deemed unnecessary.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Assets held for sale	12 Months Ended
Assets held for sale	Dec. 31, 2013
Assets held for sale [Abstract]
Assets held for sale	9. Assets held for sale During the year ended December 31, 2012, the Company completed the sale of two buildings¸ which were classified as assets held for sale, for a sales price of $12.2 million. The Company realized proceeds equal to the carrying value, less cost to sell, of these buildings and there was no gain or loss on the sale. The Company recorded the assets held for sale at fair market value, based on factors that included recent purchase offers less estimated selling costs.

Long-term debt

12 Months Ended

Dec. 31, 2013

Long-term debt [Abstract]

Long-term debt

10. Long-term debt

The components of long-term indebtedness are as follows:

	December 31,
(in thousands)	2013		2012
Construction loan dated July 2011; one month LIBOR plus 3%, repaid in December 2013	$	-	$	29,375
Equipment loan dated August 2011; one month LIBOR plus 3%, repaid in December 2013		-		11,068
Term loan dated December 2009; three month LIBOR plus 3.25%, repaid in December 2013		-		18,200
Term loan dated November 2009; three month LIBOR plus 3.25%, repaid in December 2013		-		4,131
Revolving credit loan dated December 2013; one month LIBOR plus 2.75%; due in December 2018		62,000		-
Total long-term indebtedness		62,000		62,774
Less current portion of long-term indebtedness		-		(4,470	)
Noncurrent portion of long-term indebtedness		62,000		58,304

On December 11, 2013, the Company entered into a senior secured credit agreement ("Credit Agreement") with three lending financial institutions (the "Lenders"), led by Bank of America, N.A., as administrative agent for certain other lending financial institutions. The Credit Agreement provides for a revolving credit facility of up to $100 million through December 11, 2018 (or such earlier date required by the terms of the Credit Agreement) and a term loan facility of up to $125 million to be drawn in full, if at all, on or prior to March 31, 2014. In connection with the entry into the Credit Agreement, borrowed $62.0 million under the revolving credit facility primarily to repay obligations under existing loan agreements. As of December 31, 2013, $62.0 million was outstanding under the revolving credit facility. Debt issuance costs of $3.5 million have been capitalized and are being amortized over the term of the Credit Agreement, with an unamortized balance of $3.4 million at December 31, 2013.

The Company's payment obligations under the Credit Agreement are secured by a lien on substantially all of the Company's assets, including the stock of all of the Company's subsidiaries, and the assets of the subsidiary guarantors, including mortgages over certain of their real properties, including the Company's large-scale vaccine manufacturing facility in Lansing, Michigan and the Company's product development and manufacturing facility in Baltimore, Maryland.

Under the Credit Agreement, the Company is required to make quarterly interest payments calculated using a combination of conventional base-rate measures plus a margin over those rates. The base rates consist of LIBOR rates and prime rates. The actual rates will depend on the level of these underlying rates plus a margin based on the Company's leverage, on a consolidated basis, from quarter to quarter.

The Credit Agreement contains affirmative and negative covenants customary for financings of this type. Negative covenants in the Credit Agreement, among other things, limit the Company's ability to incur indebtedness (other than the issuance of the notes in this offering) and liens; dispose of assets; make investments including loans, advances or guarantees; and enter into certain mergers or similar transactions. The Credit Agreement also contains financial covenants, tested quarterly and in connection with any triggering events under the Credit Agreement: (1) a minimum consolidated debt service coverage ratio of 2.50 to 1.00, (2) a maximum consolidated leverage ratio of 3.50 to 1.00, (3) a maximum consolidated senior leverage ratio of 2.00 to 1.00 (when no term loan is outstanding) and (4) a minimum liquidity requirement of $50 million. Upon the occurrence and continuance of an event of default under the Credit Agreement, the commitments of the lenders to make loans under the Credit Agreement may be terminated (other than commitments to make the term loan, which may only be terminated upon the occurrence and continuance of certain specified defaults) and the Company's payment obligations under the Credit Agreement may be accelerated. The events of default under the Credit Agreement include, among others, subject in some cases to specified cure periods, payment defaults; inaccuracy of representations and warranties in any material respect; defaults in the observance or performance of covenants; bankruptcy and insolvency related defaults; the entry of a final judgment in excess of a threshold amount; change of control; and the invalidity of loan documents relating to the Credit Agreement. The Company was in compliance with these covenants as of December 31, 2013.

In August 2011, the Company entered into a loan agreement with PNC Bank ("PNC") to provide the Company with an equipment loan of up to $12.0 million to fund equipment purchases at the Company's Baltimore, Maryland product development and manufacturing facility. Under the equipment loan agreement, PNC agreed to make advances to the Company of up to $12.0 million through December 2012 based on periodic requests from the Company. The loan was repaid in December 2013.

In July 2011, the Company entered into a loan agreement and related agreements with PNC, under which PNC agreed to provide the Company with a construction loan of up to $30.0 million, primarily to fund the renovation and improvement of the Baltimore facility. Under the Company's loan agreement with PNC, PNC agreed to make advances to the Company of up to $30.0 million through July 2012. This loan was repaid in December 2013.

In December 2009, the Company entered into a loan agreement with HSBC, under which HSBC provided the Company with a term loan of $22.8 million. Payment of the loan was secured by substantially all of the assets of Emergent BioDefense Operations, other than accounts receivable under BioThrax supply contracts with the U.S. government. The Company repaid the loan in December 2013.

In October 2009, the Company acquired a research and development facility in Gaithersburg, Maryland. The loan was collateralized by the facility. The Company repaid the loan in December 2013.

Scheduled principal repayments and maturities on long-term debt as of December 31, 2013 are as follows:

(in thousands)
2014		-
2015		-
2016		-
2017		-
2018 and thereafter		62,000
	$	62,000

On January 29, 2014, the Company issued $250.0 million aggregate principal amount of 2.875% Convertible Senior Notes due 2021 ("Notes"). The Notes will bear interest at a rate of 2.875% per year, payable semi-annually in arrears on January 15 and July 15 of each year, commencing July 15, 2014. The Notes will mature on January 15, 2021, unless earlier purchased by us, redeemed or converted. The conversion rate will initially equal 30.8821 shares of common stock per $1,000 principal amount of notes (which is equivalent to an initial conversion price of approximately $32.38 per share of common stock). The conversion rate will be subject to adjustment upon the occurrence of certain specified events but will not be adjusted for accrued and unpaid interest.

On January 29, 2014, in connection with the Company's issuance of the Notes, the unused $125 million term loan portion of the Company's Credit Agreement terminated automatically in accordance with the terms of the senior secured credit agreement, dated December 11, 2013, with the Lenders. In addition, following the closing of the Notes offering, we repaid the $62.0 million outstanding indebtedness under the revolving credit portion of the credit facility, which restored the full $100.0 million revolving credit capacity under this facility.

Stockholders' equity

12 Months Ended

Dec. 31, 2013

Stockholders' equity [Abstract]

Stockholders' equity

11. Stockholders' equity

Preferred stock

The Company is authorized to issue up to 15,000,000 shares of preferred stock, $0.001 par value per share ("Preferred Stock"). Any Preferred Stock issued may have dividend rights, voting rights, conversion privileges, redemption characteristics, and sinking fund requirements as approved by the Company's board of directors.

Common stock

The Company currently has one class of common stock, $0.001 par value per share common stock ("Common Stock"), authorized and outstanding. The Company is authorized to issue up to 100,000,000 shares of Common Stock. Holders of Common Stock are entitled to one vote for each share of Common Stock held on all matters, except as may be provided by law.

Treasury stock

On May 17, 2012, the Company's Board of Directors authorized the repurchase of up to $35.0 million of its common stock through a share repurchase program. The Company repurchased 398,481 shares for $5.8 million during the year ended December 31, 2012. There were no repurchases under the plan during the year ended December 31, 2013. The repurchase program terminated on December 31, 2013. In addition, the Company has acquired 14,472 shares, through December 31, 2013, from members of senior management for $287,000.

Employee Stock Purchase Plan

On May 17, 2012, the Company's shareholders approved the 2012 Employee Stock Purchase Plan ("ESPP"), as defined in Section 423 of the Internal Revenue Code of 1986. All employees of the Company are eligible to participate in the ESPP, except those owning 5% or more of the Company's stock. one million shares of common stock have been approved for the ESPP. The ESPP has two plan periods: December 1^st to May 31^st and June 1^st to November 30^th. Employees are permitted to contribute between 1% and 10% of compensation during a plan period. The ESPP allows for employees to purchase shares of the Company's stock at a 15% discount at the end of each plan period based on the share price at that time. The maximum number of shares an employee may purchase during any plan period is 800 shares. The Company utilizes the Black-Scholes valuation model for estimating the fair value of all shares under its ESPP. The fair value of each ESPP share is estimated at the beginning of each plan period. During the year ended December 31, 2013, the Company issued 52,768 shares under the ESPP plan. During the year ended December 31, 2013, the Company recorded stock-based compensation expense of $128,000 related to the ESPP.

Stock options and restricted stock units

The following is a summary of option award activity under the Emergent Plans:

	2006 Plan					2004 Plan
	Number of Shares			Weighted-Average Exercise Price		Number of Shares		Weighted-Average Exercise Price		Aggregate Intrinsic Value
Outstanding at December 31, 2012		3,549,842		$	17.08		53,156	$	8.86	$	4,801,378
Exercisable at December 31, 2012		2,144,732		$	16.25		53,156	$	8.86	$	4,476,830
Granted		993,544			15.21		-		-
Exercised		(481,549	)		12.61		-		-
Forfeited		(419,742	)		18.34		-		-
Outstanding at December 31, 2013		3,642,095		$	17.01		53,156	$	8.86	$	23,148,738
Exercisable at December 31, 2013		2,074,772		$	17.44		53,156	$	8.86	$	12,685,394
Options expected to vest at December 31, 2013		1,171,171		$	16.44		-	$	-	$	7,820,256

The following is a summary of restricted stock unit award activity under the 2006 Plan:

	Number of Shares			Weighted-Average Grant Price		Aggregate Intrinsic Value
Outstanding at December 31, 2012		715,276		$	18.41	$	11,473,027
Granted		496,771			15.21
Vested		(337,498	)		14.91
Forfeited		(80,873	)		16.72
Outstanding at December 31, 2013		793,676		$	16.52	$	18,246,611

The weighted average remaining contractual term of options outstanding as of December 31, 2013 and 2012 was 4.1 and 4.2 years, respectively. The weighted average remaining contractual term of options exercisable as of December 31, 2013 and 2012 was 3.4 and 3.5 years, respectively.

The weighted average grant date fair value of options granted during the years ended December 31, 2013, 2012 and 2011 was $5.38, $5.16 and $10.09 respectively. The total intrinsic value of options exercised during the years ended December 31, 2013, 2012 and 2011 was $6.9 million, $589,000 and $10.2 million, respectively. The total fair value of awards vested during 2013, 2012 and 2011 was $9.1 million, $10.3 million and $7.9 million, respectively.

Stock-based compensation expense from the 2006 Plan was recorded in the following financial statement line items:

	Years Ended
	December 31,
(in thousands)	2013			2012			2011
Cost of product sales		$	575		$	513		$	466
Research and development			3,283			3,451			3,203
General and administrative			7,252			7,151			7,070
Total stock-based compensation expense		$	11,110		$	11,115		$	10,739

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Income taxes

12 Months Ended

Dec. 31, 2013

Income taxes [Abstract]

Income taxes

12. Income taxes

Significant components of the provision for income taxes attributable to operations consist of the following:

	Year ended December 31,
(in thousands)	2013			2012			2011
Current
Federal	$	(878	)	$	11,481		$	11,481
State		(173	)		(1,045	)		(1,045	)
International		300			103			103
Total current		(751	)		10,539			10,539
Deferred
Federal		12,679			3,758			3,758
State		1,028			(375	)		(375	)
International		152			-			-
Total deferred		13,859			3,383			3,383
Total provision for income taxes	$	13,108		$	13,922		$	13,922

The Company's net deferred tax asset consists of the following:

	December 31,
(in thousands)	2013			2012
Net operating loss carryforward	$	23,256		$	26,102
Research and development carryforward		7,395			3,556
Stock compensation		6,378			5,289
Foreign deferrals		64,090			64,009
Deferred revenue		-			-
Other		4,522			9,005
Deferred tax asset		105,641			107,961
Fixed assets		(32,588	)		(22,040	)
Other		(5,714	)		(6,158	)
Deferred tax liability		(38,302	)		(28,198	)
Valuation allowance		(68,846	)		(67,412	)
Net deferred tax (liabilities)/assets	$	(1,507	)	$	12,351

The Company currently has approximately $34.1 million in net operating loss carryforwards along with $7.4 million in research and development tax credit carryforwards for U.S. federal tax purposes that will begin to expire in 2026 and 2023, respectively. The U.S. federal tax carryforwards are recorded with no valuation allowance. The Company has $211.5 million in state net operating loss carryforwards, primarily in Maryland, that will begin to expire in 2018. The Company has approximately $227.6 million in net operating losses from foreign jurisdictions that will have an indefinite life unless the foreign entities have a change in the nature or conduct of the business in the three years following a change in ownership. These foreign net operating losses are recorded with a valuation allowance as their realization is not more-likely-than-not. The use of any of these net operating losses and research and development tax credit carryforwards may be restricted due to changes in the Company's ownership.

The provision for income taxes differs from the amount of taxes determined by applying the U.S. federal statutory rate to loss before provision for income taxes as a result of the following:

	Year ended December 31,
(in thousands)	2013			2012			2011
US	$	52,749		$	52,391		$	66,756
International		(8,506	)		(14,945	)		(27,907	)
Earnings before taxes on income		44,243			37,446			38,849

Federal tax at statutory rates	$	15,485		$	13,106		$	13,597
State taxes, net of federal benefit		538			(2,079	)		46
Impact of foreign operations		(1,116	)		(3,604	)		(2,371	)
Change in valuation allowance		1,434			4,629			3,193
Effect of foreign rates		-			(22	)		(12	)
Tax credits		(5,918	)		(2,904	)		(1,405	)
Other differences		(227	)		139			556
Permanent differences		2,912			4,657			2,226
Provision for income taxes	$	13,108		$	13,922		$	15,830

The effective annual tax rate for the years ended December 31, 2013, 2012 and 2011 was 30%, 37% and 41%, respectively. The decrease in the effective annual tax rate in 2013 from 2012 is primarily related to research and development tax credits and orphan drug tax credits related to our otlertuzumab (formely TRU-016) product candidate. The decrease in the effective annual tax rate in 2012 from 2011 is primarily related to orphan drug tax credits related to our otlertuzumab (formerly TRU-016) product candidate.

The Company recognizes interest in interest expense and recognizes potential penalties related to unrecognized tax benefits in selling, general and administrative expense. The Company accrued approximately $15,000 and $25,000 for the payment of interest and penalties as of December 31, 2013 and 2012, respectively. Of the total unrecognized tax benefits recorded at December 31, 2013 and 2012, $132,000 and $153,000, respectively, is classified as a current liability and $991,000 and $863,000, respectively, is classified as a non-current liability on the balance sheet. As of December 31, 2013 and 2012, $152,000 and $75,000, respectively, of unrecognized tax benefits will reverse within the next twelve months.

The table below presents the gross unrecognized tax benefits activity for 2013, 2012 and 2011:

(in thousands)
Gross unrecognized tax benefits at January 1, 2011	$	950
Increases for tax positions for prior years		167
Decreases for tax positions for prior years		(61	)
Increases for tax positions for current year		-
Settlements		-
Lapse of statute of limitations		-
Gross unrecognized tax benefits at December 31, 2011		1,056
Increases for tax positions for prior years		25
Decreases for tax positions for prior years		(65	)
Increases for tax positions for current year		-
Settlements		-
Lapse of statute of limitations		-
Gross unrecognized tax benefits at December 31, 2012		1,016
Increases for tax positions for prior years		165
Decreases for tax positions for prior years		-
Increases for tax positions for current year		15
Settlements		-
Lapse of statute of limitations		(75	)
Gross unrecognized tax benefits at December 31, 2013	$	1,121

When resolved, substantially all of these reserves would impact the effective tax rate.

The Company's federal and state income tax returns for the tax years 2010 to 2012 remain open to examination. The Company's tax returns in the United Kingdom remain open to examination for the tax years 2006 to 2013, and tax returns in Germany remain open indefinitely.

As of December 31, 2013, the Company's 2008, 2009 and 2010 federal income tax returns are in appeals with the Internal Revenue service. The Company believes appropriate provisions have been made for any outstanding issues.

Variable interest entities	12 Months Ended
Variable interest entities	Dec. 31, 2013
Variable interest entities [Abstract]
Variable interest entities	13. Variable interest entities In July 2008, the Company entered into a collaboration with the University of Oxford ("Oxford") and certain Oxford researchers to advance a vaccine product candidate for tuberculosis, resulting in the formation of the Oxford-Emergent Tuberculosis Consortium ("OETC"). As a result of clinical trial data for the Company's tuberculosis vaccine product candidate published in February 2013, the Company expects future funding of OETC to be minimal. The Company evaluates its variable interests in OETC on a quarterly basis and has determined that it is the primary beneficiary as it has the power to direct the activities of OETC that most significantly impact OETC's economic performance and will absorb the majority of expected losses. Accordingly, the Company consolidates OETC. As of December 31, 2013 and 2012, respectively, assets of $305,000 and $2.0 million and liabilities of $249,000 and $2.0 million related to OETC were included within the Company's consolidated balance sheets. During the year ended December 31, 2013, 2012 and 2011, OETC incurred a net loss of $1.8 million, $10.7 million and $13.2 million, respectively, of which, $910,000, $5.4 million and $6.7 million, respectively, is included in the Company's consolidated statement of operations. In addition, the Company reclassified $83,000 of accumulated translation adjustments. This reclassification was recorded as selling, general and administrative expense within the Company's Biosciences segment. In conjunction with the establishment of OETC, the Company granted a put option to Oxford and certain Oxford researchers whereby the Company may be required to acquire all of the OETC shares held by Oxford and the Oxford researchers at the fair market value of the underlying shares. This put option is contingent upon the satisfaction of a number of conditions that must exist or occur subsequent to the granting by the European Commission of marketing authorization for the OETC-sponsored tuberculosis vaccine product candidate. The Company accounts for the put option in accordance with the accounting provisions related to derivatives and distinguishing liabilities from equity. In accordance with these provisions, the Company has determined that the put option had no value as of December 31, 2013 and 2012.

Collaboration Agreements	12 Months Ended
Collaboration Agreements	Dec. 31, 2013
Collaboration Agreements [Abstract]
Collaboration Agreements	14. Collaboration agreements Abbott Laboratories In August 2009, Trubion, which the Company acquired in October 2010, entered into a collaboration agreement with Facet Biotech Corporation, now a wholly-owned subsidiary of Abbott, for the joint worldwide development and commercialization of otlertuzumab (formerly TRU-016). The collaboration agreement covered otlertuzumab (formerly TRU-016) in all indications and all other CD37-directed protein therapeutics. The collaboration agreement was terminated on March 20, 2012 and all rights to otlertuzumab (formerly TRU-016) and other CD37-directed protein therapeutics under the collaboration agreement reverted back to the Company. During the year ended December 31, 2012 and 2011, the Company recorded revenue of $2.7 million and $17.7 million, respectively, for research and development services pursuant to the Abbott agreement, which are included in the Company's financial statements of operations as contracts and grants revenue within the Company's Biosciences segment. For the year ended December 31, 2012, the Company recorded $1.4 million related to deferred revenue recognition and $1.4 million for collaborative research funding. For the year ended December 31, 2011, the revenue is comprised of $10.5 million related to the recognition of deferred revenue, $6.0 million related to the achievement of a development milestone and $1.2 million for collaborative research funding. Pfizer Inc. In December 2005, Trubion entered into an agreement (the "Pfizer Agreement") with Wyeth Pharmaceuticals, now a wholly-owned subsidiary of Pfizer, for the development and worldwide commercialization of CD20-directed therapeutics. In May 2011, the Company and Pfizer entered into an amendment to the Pfizer Agreement which released certain restrictions related to the devleopment and commercialization of Biosilimiar CD-20 antibodies ("Biosimilar Agreement"). In September 2012, the Pfizer Agreement was terminated. The Company's right to receive royalty payments under the Biosiliar Agreement survives termination of the Pfizer Agreement. During the year ended December 31, 2012 and 2011, the Company recorded revenue of $1.2 million and $1.9 million, respectively, for research and development services pursuant to the Pfizer agreement, which are included in the Company's financial statements of operations as contracts and grants revenue within the Company's Biosciences segment. For the year ended December 31, 2012, the Company recorded $68,000 related to deferred revenue recognition and $1.1 million for collaborative research funding. For the year ended December 31, 2011, the revenue is comprised of $52,000 related to the recognition of deferred revenue and $1.8 million for collaborative research funding.

Restructuring

12 Months Ended

Dec. 31, 2013

Restructuring [Abstract]

Restructuring

15. Restructuring

In February 2013, the Company adopted a plan to restructure the operations of Emergent Product Development UK Limited ("EPDU") and OETC due to the results of the Phase IIb clinical trial for the Company's tuberculosis vaccine product candidate. The Company completed this restructuring as of June 30, 2013, except for the payment of certain termination benefit obligations that remain payable as of December 31, 2013.

The restructuring plan included a headcount reduction of 14 employees at EPDU, the termination of a facility lease, and the impairment of leasehold improvements and equipment. These costs, which are included in selling, general and administrative expense in the Company's statement of operations and are included within the Biosciences segment, are detailed below:

	Incurred during
	the year ended
(in thousands)	December 31, 2013
Termination benefits	$	2,114
Contract termination costs		431
Other costs		261
Total	$	2,806

The following is a summary of the activity for the liabilities related to the EPDU restructuring:

				Contract
	Termination			Termination			Other
(in thousands)	Benefits			Costs			Costs			Total
Balance at December 31, 2012	$	-			-		$	-		$	-
Expenses incurred		2,114			431			134			2,679
Amount paid		(1,660	)		(431	)		(134	)		(2,225	)
Other adjustments		-			-			-			-
Balance at December 31, 2013	$	454		$	-			-		$	454

401(k) savings plan	12 Months Ended
401(k) savings plan	Dec. 31, 2013
401(k) savings plan [Abstract]
401(k) savings plan	16. 401(k) savings plan The Company has established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. The 401(k) Plan covers substantially all employees. Under the 401(k) Plan, employees may make elective salary deferrals. The Company currently provides for matching of qualified deferrals up to 50% of the first 6% of the employee's salary. During the years ended December 31, 2013, 2012 and 2011, the Company made matching contributions of approximately $2.0 million, $1.9 million and $1.8 million, respectively.

Leases

12 Months Ended

Dec. 31, 2013

Leases [Abstract]

Leases

17. Leases

The Company leases laboratory and office facilities, office equipment and vehicles under various operating lease agreements. The Company leases office space and laboratory space in Munich, Germany under a non-cancelable operating lease that expires in June 2015. The Company leases primarily office space in Wokingham, England under an operating lease that expires in November 2016. The Company leases office space in Rockville, Maryland under an operating lease that contains a 3% annual escalation clause, which expires in December 2016, and includes an early termination date of January 2014. The Company leases office and laboratory space under an operating lease agreement in Seattle, Washington, which expires in April 2015. For the years ended December 31, 2013, 2012 and 2011, total lease expense was $3.9 million, $3.6 million and $3.8 million, respectively. For the year ended December 31, 2013, the Company recorded lease income of $446,000.

Future minimum lease payments under operating lease obligations as of December 31, 2013 were as follows:

(in thousands)
2014		3,151
2015		1,981
2016		1,217
2017		-
Total minimum lease payments		6,349
Minimum lease receipts		(5,938	)

Total net minimum lease payments	$	411

Business interruption insurance recovery	12 Months Ended
Business interruption insurance recovery	Dec. 31, 2013
Business interruption insurance recovery [Abstract]
Business interruption insurance recovery	18. Business interruption insurance recovery During the year ended December 31, 2012, the Company recorded a $1.7 million in insurance recovery related to a power outage at its Lansing, Michigan facility. The insurance recovery is classified in the Company's statement of operations as other income (expense), net.

Related party transactions	12 Months Ended
Related party transactions	Dec. 31, 2013
Related party transactions [Abstract]
Related party transactions	19. Related party transactions The Company entered into an agreement in February 2009 with an entity controlled by family members of the Company's Executive Chairman to market and sell BioThrax. The agreement was effective as of November 2008 and requires payment based on a percentage of net sales of biodefense products of 17.5% in Saudi Arabia and 15% in Qatar and United Arab Emirates, and reimbursement of certain expenses. No expenses were incurred under this agreement during 2013 and 2012. The Company entered into a consulting agreement in September 2010 with an entity controlled by the Company's former Senior Vice President Corporate Affairs, who is also a family member of the Company's Executive Chairman. The agreement, which terminated in August 2011, provided for consulting services in connection with special projects as assigned by the Company's President. During 2011, the Company incurred approximately $35,000 for services rendered under this agreement, of which no balance remained in unpaid accounts payable at December 31, 2011. The Company was previously a party to a consulting agreement with a member of the Company's Board of Directors. In October 2011, this director resigned from the Company's Board of Directors, and the consulting agreement was terminated in November 2011. During the year ended 2011, the Company incurred approximately $225,000 under this agreement for strategic consultation and project support for the Company's marketing and communications group, of which no balance remained unpaid in accounts payable at December 31, 2011.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Earnings per share

12 Months Ended

Dec. 31, 2013

Earnings per share [Abstract]

Earnings per share

20. Earnings per share

The following table presents the calculation of basic and diluted net income per share:

	Year Ended December 31,
(in thousands, except share and per share data)	2013		2012		2011
Numerator:
Net income	$	31,135	$	23,524	$	23,019

Denominator:
Weighted-average number of shares—basic		36,201,283		36,080,495		35,658,907
Dilutive securities—equity awards		546,273		340,167		547,145
Weighted-average number of shares—diluted		36,747,556		36,420,662		36,206,052

Earnings per share-basic	$	0.86	$	0.65	$	0.65
Earnings per share-diluted	$	0.85	$	0.65	$	0.64

For the years ending December 31, 2013, 2012 and 2011, outstanding stock options to purchase approximately 1.5 million, 2.9 million and 746,000 shares of common stock, respectively, are not considered in the diluted earnings per share calculation because the exercise price of these options is greater than the average per share closing price during the year.

Segment information

12 Months Ended

Dec. 31, 2013

Segment information [Abstract]

Segment information

21. Segment information

For financial reporting purposes, the Company reports financial information for two business segments: Biodefense and Biosciences. The Company's two business segments, or divisions, engage in business activities for which discrete financial information is reviewed by the chief operating decision maker. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company's reportable segments are business units that offer different products and product candidates and are managed separately because they manufacture and develop distinct products with different development processes.

The Biodefense division is directed to government-sponsored development and supply of countermeasures against potential agents of bioterror or biowarfare and targets the infectious disease anthrax. Revenues in this segment are primarily from sales of the Company's FDA-licensed product, BioThrax® (Anthrax Vaccine Adsorbed), to the U.S. government. The Biosciences division is directed to commercial opportunities and primarily targets oncology indications, and consists of two business units, therapeutics and vaccines. The "All Other" segment relates to the general operating costs of the Company and includes costs of the centralized services departments, which are not allocated to the other segments, as well as spending on activities that are not classified as Biodefense or Biosciences. The assets in this segment consist primarily of cash.

	Reportable Segments
(in thousands)	Biodefense		Biosciences			All Other			Total
Year Ended December 31, 2013
External revenue	$	311,564	$	1,181		$	-		$	312,745
Intersegment revenue (expense)		-		-			-			-
Research and development		62,663		50,652			6,618			119,933
Interest income		-		-			139			139
Interest expense		-		-			-			-
Depreciation and amortization		17,534		1,238			186			18,958
Net income (loss)		87,289		(50,925	)		(5,229	)		31,135
Intangible assets		30,148		-			-			30,148
In-process research and development assets		-		41,800			-			41,800
Goodwill		8,452		5,502						13,954
Total assets		331,827		98,510			196,293			626,630
Expenditures for long-lived assets		30,700		1,343			9,978			42,021
Year Ended December 31, 2012
External revenue	$	276,469	$	5,419		$	-		$	281,888
Intersegment revenue (expense)		-		-			-			-
Research and development		68,579		44,588			7,059			120,226
Interest income		-		-			134			134
Interest expense		-		-			(6	)		(6	)
Depreciation and amortization		8,951		2,147			99			11,197
Net income (loss)		94,865		(63,928	)		(7,413	)		23,524
In-process research and development assets		-		41,800			-			41,800
Goodwill		-		5,502			-			5,502
Total assets		354,010		56,148			154,072			564,230
Expenditures for long-lived assets		52,957		810			78			53,845
Year Ended December 31, 2011
External revenue	$	251,037	$	22,347		$	-		$	273,384
Intersegment revenue (expense)		-		-			-			-
Research and development		57,833		61,566			5,433			124,832
Interest income		-		-			105			105
Interest expense		-		-			-			-
Depreciation and amortization		6,213		3,070			72			9,355
Net income (loss)		86,836		(56,438	)		(7,379	)		23,019
In-process research and development assets		-		51,400			-			51,400
Goodwill		-		5,502			-			5,502
Total assets		290,302		92,321			164,241			546,864
Expenditures for long-lived assets		52,326		1,608			92			54,026

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

+ Details

Quarterly financial data (unaudited)

12 Months Ended

Dec. 31, 2013

Quarterly financial data (unaudited) [Abstract]

Quarterly financial data (unaudited)

22. Quarterly financial data (unaudited)

Quarterly financial information for the years ended December 31, 2013 and 2012 is presented in the following tables:

	Three months ended
(in thousands)	March 31,			June 30,		September 30,		December 31,
Fiscal year 2013
Revenue	$	43,100		$	82,436	$	89,102	$	98,107
Income (loss) from operations		(13,350	)		14,712		18,147		23,293
Net income (loss)		(8,062	)		10,484		13,491		15,222
Net income (loss) per share, basic		(0.22	)		0.29		0.37		0.42
Net income (loss) per share, diluted		(0.22	)		0.29		0.36		0.41
Fiscal year 2012
Revenue	$	50,311		$	70,379	$	66,592	$	94,606
Income (loss) from operations		(12,538	)		8,653		9,817		24,035
Net income (loss)		(6,829	)		7,632		6,617		16,104
Net income (loss) per share, basic		(0.19	)		0.21		0.18		0.45
Net income (loss) per share, diluted		(0.19	)		0.21		0.18		0.44

Subsequent events

12 Months Ended

Dec. 31, 2013

Subsequent events [Abstract]

Subsequent events

23. Subsequent events

On December 11, 2013, the Company entered into an arrangement agreement with Cangene Corporation ("Cangene") pursuant to which one of Emergent's wholly-owned subsidiaries will acquire all of the outstanding common shares of Cangene (the "Arrangement"), for $3.24 per share in cash (on a fully diluted basis), which represents a total purchase price of $222 million. This transaction will be accounted for by the Company under the acquisition method of accounting, with the Company as the acquiror. Under the acquisition method of accounting, the assets and liabilities of Cangene will be recorded as of the acquisition date, at their respective fair values, and combined with those of the Company. The Arrangement closed on February 21, 2014.

The table below summarizes the preliminary allocation of the purchase price based upon estimated fair values of assets acquired and liabilities assumed at February 21, 2014. As of the date of this filing, the valuation of acquired intangible assets, inventory, deferred taxes, property plant and equipment, contingent purchase consideration and other fair value adjustments are not complete, and as such the purchase price allocation is subject to change.

(in thousands)	February 21, 2014


Estimated fair value of tangible assets acquired and liabilities assumed:
Acquired tangible assets (i)	$	202,500
Assumed tangible liabilities		(38,300	)
Total estimated fair value of tangible assets acquired and liabilities assumed		164,200

Identified intangible assets		52,500
Deferred tax liability associated with identified intangible assets		(3,000	)
		49,500

Goodwill		8,300

Total preliminary estimated purchase price	$	222,000

(i)

Acquired tangible assets reflect a $12.3 million adjustment to record inventory at fair value, referred to as a step-up adjustment. The $12.3 million step-up was estimated to be amortized through cost of product sales and contract manufacturing over the next five years based on estimated inventory turnover which, will increase costs of product sales during such period.

The table below summarizes the preliminary estimated fair value of intangible assets acquired and the estimated amortization periods:

			Amortization
			Period
($ in thousands)	Amount		in years


Corporate trade name	$	2,600		5.0
Marketed products		5,100		15.0
Licensed products		1,900		3.0
Biodefense		34,400		15.0
Contract manufacturing		8,500		15.0

Total identified intangible assets	$	52,500

The Company determined the estimated fair value of the intangibles assets using the income approach, which is based on the present value of future cash flows. The fair value measurements are based on significant unobservable inputs, that are developed by the Company using estimates and assumptions of the respective market and market penetration of the Company's products.

The Company will record approximately $8.3 million in goodwill related to the Cangene acquisition representing the purchase price paid in the acquisition that was in excess of the fair value of the tangible and intangible assets acquired. None of the goodwill generated from the Cangene acquisition is expected to be deductible for tax purposes.

The Company has incurred transaction costs related to the Cangene acquisition of approximately $3.3 million for the year ended December 31, 2013, which have been recorded in selling, general and administrative expenses within the Company's Biosciences segment.

The following pro forma information is presented as if the acqusition had occurred on January 1, 2012, and combines the historical results of operations of the Company and Cangene for the years ended December 31, 2013 and 2012.

	December 31,
(in thousands, except per share data)	2013		2012
Pro forma revenue	$	440,320	$	400,269
Pro forma net income	$	13,914	$	2,171

Summary of significant accounting policies (Policies)

12 Months Ended

Dec. 31, 2013

Summary of significant accounting policies [Abstract]

Basis of presentation and consolidation

Use of estimates

Cash and cash equivalents

Fair value of measurements

Level 1 —

Observable inputs for identical assets or liabilities such as quoted prices in active markets;

Level 2 —

Inputs other than quoted prices in active markets that are either directly or indirectly observable; and

Level 3 —

Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.

Significant customers and accounts receivable

Concentrations of credit risk

Inventories

Property, plant and equipment

Property, plant and equipment are stated at cost. Depreciation is computed using the straight-line method over the following estimated useful lives:

Buildings	31-39 years
Building improvements	10-39 years
Furniture and equipment	3-15 years
Software	Lesser of 3-5 years or product life
Leasehold improvements	Lesser of the asset life or lease term

Income taxes

Revenue recognition

The Company recognizes revenues from product sales if four basic criteria have been met:



there is persuasive evidence of an arrangement;



delivery has occurred or title has passed to the Company's customer;



the fee is fixed or determinable; and



collectability is reasonably assured.

Contingent purchase consideration obligations

Contingent value rights

Intangible assets and Acquired in process research and development

Intangible assets and acquired in-process research and development

§	estimating the timing of and expected costs to complete the in-process projects;

§	projecting the likelihood and timing of regulatory approvals;

§	estimating future cash flows from product sales resulting from completed products and in-process projects; and

§	developing appropriate discount rates and probability rates by project.

The Company amortizes intangible assets based on the estimated useful life.

Goodwill

Impairment of long-lived assets

Research and development

Comprehensive income

Foreign currencies

Capitalized interest

Certain risks and uncertainties

Earnings Per Share

Earnings per share

Accounting for stock-based compensation

	Year Ended December 31,
		2013	2012	2011
Expected dividend yield		0%	0%	0%
Expected volatility		39-49%	41-52%	60%
Risk-free interest rate		0.32-0.70%	0.36-0.54%	0.35-1.04%
Expected average life of options		4.4 years	3.4 years	3.4 years



Expected dividend yield — the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.



Risk-free interest rate — the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date on which the option is granted.



Summary of significant accounting policies (Tables)

12 Months Ended

Dec. 31, 2013

Summary of significant accounting policies [Abstract]

Estimated useful lives of property, plant and equipment

Property, plant and equipment are stated at cost. Depreciation is computed using the straight-line method over the following estimated useful lives:

Buildings	31-39 years
Building improvements	10-39 years
Furniture and equipment	3-15 years
Software	Lesser of 3-5 years or product life
Leasehold improvements	Lesser of the asset life or lease term

Assumptions used in valuing stock options granted

	Year Ended December 31,
		2013	2012	2011
Expected dividend yield		0%	0%	0%
Expected volatility		39-49%	41-52%	60%
Risk-free interest rate		0.32-0.70%	0.36-0.54%	0.35-1.04%
Expected average life of options		4.4 years	3.4 years	3.4 years

Acquisition of Healthcare Protective Products Division (Tables) - HPPD [Member]

12 Months Ended

Dec. 31, 2013

Business Acquisition [Line Items]

Preliminary Purchase Price

The total purchase price is summarized below:

(in thousands)
Amount of cash paid to Bracco Diagnostics Inc.	$	25,873
Fair value of contigent purchase consideration		16,232
Total purchase price	$	42,105

Purchase Price Allocation

The table below summarizes the allocation of the purchase price based upon fair values of assets acquired and liabilities assumed at August 1, 2013.

(in thousands)
Acquired intangible assets		32,099
Goodwill		8,452
Acquired equipment		1,543
Other		11
Total purchase price	$	42,105

Rollforward of Intangible Assets

Intangible assets consist of the following:

(in thousands)	RSDL			Manufacturing Agreement			Total
Cost Basis
Balance at December 31, 2012	$	–		$	–		$	–
Additions		28,621			3,478			32,099
Balance at December 31, 2013	$	28,621		$	3,478		$	32,099

Accumulated Amortization
Balance at December 31, 2012	$	–		$	–		$	–
Amortization		(1,468	)		(483	)		(1,951	)
Balance at December 31, 2013	$	(1,468	)	$	(483	)	$	(1,951	)

Net book value at December 31, 2013	$	27,153		$	2,995		$	30,148

Future Amortization Expense of Intangible Assets

Future amortization expense as of December 31, 2013 is as follows:

(in thousands)
2014	$	4,737
2015		4,737
2016		4,255
2017		3,587
2018 and beyond		12,832
Total remaining amortization	$	30,148

Fair value measurements (Tables)

12 Months Ended

Dec. 31, 2013

Fair value measurements [Abstract]

Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

	At December 31, 2013
(in thousands)		Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)		$	37,701	$	-	$	-	$	37,701
Total assets		$	37,701	$	-	$	-	$	37,701

Liabilities:
Contingent purchase consideration		$	-	$	-	$	16,619	$	16,619
Total liabilities		$	-	$	-	$	16,619	$	16,619

	At December 31, 2012
(in thousands)		Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)		$	42,720	$	-	$	-	$	42,720
Total assets		$	42,720	$	-	$	-	$	42,720

(1) Included in cash and cash equivalents in accompanying consolidated balance sheets.

Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)

(in thousands)
Balance at December 31, 2011	$	4,753
Expense (income) included in earnings		(3,005	)
Settlements		(1,748	)
Purchases, sales and issuances		-
Transfers in/(out) of Level 3		-
Balance at December 31, 2012	$	-
Expense (income) included in earnings		735
Settlements		(348	)
Purchases, sales and issuances		16,232
Transfers in/(out) of Level 3		-
Balance at December 31, 2013	$	16,619

Accounts receivable (Tables)

12 Months Ended

Dec. 31, 2013

Accounts receivable [Abstract]

Accounts receivable

Accounts receivable consist of the following:

	December 31,
(in thousands)	2013			2012
Billed		$	45,757		$	76,155
Unbilled			14,830			19,888
Total		$	60,587		$	96,043

Inventories (Tables)

12 Months Ended

Dec. 31, 2013

Inventories [Abstract]

Inventories

Inventories consist of the following:

	December 31,
(in thousands)	2013		2012
Raw materials and supplies	$	2,656	$	2,733
Work-in-process		9,819		9,813
Finished goods		2,168		2,615
Total inventories	$	14,643	$	15,161

Property, plant and equipment (Tables)

12 Months Ended

Dec. 31, 2013

Property, plant and equipment [Abstract]

Property, plant and equipment

Property, plant and equipment consist of the following:

	December 31,
(in thousands)	2013			2012
Land and improvements	$	10,605		$	4,839
Buildings, building improvements and leasehold improvements		83,823			66,953
Furniture and equipment		107,006			91,772
Software		21,832			15,691
Construction-in-progress		98,345			105,452
		321,611			284,707
Less: Accumulated depreciation and amortization		(57,371	)		(42,943	)
Total property, plant and equipment, net	$	264,240		$	241,764

Long-term debt (Tables)

12 Months Ended

Dec. 31, 2013

Long-term debt [Abstract]

Components of long-term indebtedness

The components of long-term indebtedness are as follows:

	December 31,
(in thousands)	2013		2012
Construction loan dated July 2011; one month LIBOR plus 3%, repaid in December 2013	$	-	$	29,375
Equipment loan dated August 2011; one month LIBOR plus 3%, repaid in December 2013		-		11,068
Term loan dated December 2009; three month LIBOR plus 3.25%, repaid in December 2013		-		18,200
Term loan dated November 2009; three month LIBOR plus 3.25%, repaid in December 2013		-		4,131
Revolving credit loan dated December 2013; one month LIBOR plus 2.75%; due in December 2018		62,000		-
Total long-term indebtedness		62,000		62,774
Less current portion of long-term indebtedness		-		(4,470	)
Noncurrent portion of long-term indebtedness		62,000		58,304

Schedule of Maturities of Long-term Debt

Scheduled principal repayments and maturities on long-term debt as of December 31, 2013 are as follows:

(in thousands)
2014		-
2015		-
2016		-
2017		-
2018 and thereafter		62,000
	$	62,000

Stockholders' equity (Tables)

12 Months Ended

Dec. 31, 2013

Stockholders' equity [Abstract]

Option award activity

The following is a summary of option award activity under the Emergent Plans:

	2006 Plan					2004 Plan
	Number of Shares			Weighted-Average Exercise Price		Number of Shares		Weighted-Average Exercise Price		Aggregate Intrinsic Value
Outstanding at December 31, 2012		3,549,842		$	17.08		53,156	$	8.86	$	4,801,378
Exercisable at December 31, 2012		2,144,732		$	16.25		53,156	$	8.86	$	4,476,830
Granted		993,544			15.21		-		-
Exercised		(481,549	)		12.61		-		-
Forfeited		(419,742	)		18.34		-		-
Outstanding at December 31, 2013		3,642,095		$	17.01		53,156	$	8.86	$	23,148,738
Exercisable at December 31, 2013		2,074,772		$	17.44		53,156	$	8.86	$	12,685,394
Options expected to vest at December 31, 2013		1,171,171		$	16.44		-	$	-	$	7,820,256

Restricted stock units activity

The following is a summary of restricted stock unit award activity under the 2006 Plan:

	Number of Shares			Weighted-Average Grant Price		Aggregate Intrinsic Value
Outstanding at December 31, 2012		715,276		$	18.41	$	11,473,027
Granted		496,771			15.21
Vested		(337,498	)		14.91
Forfeited		(80,873	)		16.72
Outstanding at December 31, 2013		793,676		$	16.52	$	18,246,611

Allocated stock-based compensation expense

Stock-based compensation expense from the 2006 Plan was recorded in the following financial statement line items:

	Years Ended
	December 31,
(in thousands)	2013			2012			2011
Cost of product sales		$	575		$	513		$	466
Research and development			3,283			3,451			3,203
General and administrative			7,252			7,151			7,070
Total stock-based compensation expense		$	11,110		$	11,115		$	10,739

Income taxes (Tables)

12 Months Ended

Dec. 31, 2013

Income taxes [Abstract]

Components of the provision for income taxes attributable to operations

Significant components of the provision for income taxes attributable to operations consist of the following:

	Year ended December 31,
(in thousands)	2013			2012			2011
Current
Federal	$	(878	)	$	11,481		$	11,481
State		(173	)		(1,045	)		(1,045	)
International		300			103			103
Total current		(751	)		10,539			10,539
Deferred
Federal		12,679			3,758			3,758
State		1,028			(375	)		(375	)
International		152			-			-
Total deferred		13,859			3,383			3,383
Total provision for income taxes	$	13,108		$	13,922		$	13,922

Net deferred tax asset

The Company's net deferred tax asset consists of the following:

	December 31,
(in thousands)	2013			2012
Net operating loss carryforward	$	23,256		$	26,102
Research and development carryforward		7,395			3,556
Stock compensation		6,378			5,289
Foreign deferrals		64,090			64,009
Deferred revenue		-			-
Other		4,522			9,005
Deferred tax asset		105,641			107,961
Fixed assets		(32,588	)		(22,040	)
Other		(5,714	)		(6,158	)
Deferred tax liability		(38,302	)		(28,198	)
Valuation allowance		(68,846	)		(67,412	)
Net deferred tax (liabilities)/assets	$	(1,507	)	$	12,351

Reconciliation of taxes determined by applying U.S. federal statutory rate to loss before provision for income taxes

The provision for income taxes differs from the amount of taxes determined by applying the U.S. federal statutory rate to loss before provision for income taxes as a result of the following:

	Year ended December 31,
(in thousands)	2013			2012			2011
US	$	52,749		$	52,391		$	66,756
International		(8,506	)		(14,945	)		(27,907	)
Earnings before taxes on income		44,243			37,446			38,849

Federal tax at statutory rates	$	15,485		$	13,106		$	13,597
State taxes, net of federal benefit		538			(2,079	)		46
Impact of foreign operations		(1,116	)		(3,604	)		(2,371	)
Change in valuation allowance		1,434			4,629			3,193
Effect of foreign rates		-			(22	)		(12	)
Tax credits		(5,918	)		(2,904	)		(1,405	)
Other differences		(227	)		139			556
Permanent differences		2,912			4,657			2,226
Provision for income taxes	$	13,108		$	13,922		$	15,830

Gross unrecognized tax benefits activity

The table below presents the gross unrecognized tax benefits activity for 2013, 2012 and 2011:

(in thousands)
Gross unrecognized tax benefits at January 1, 2011	$	950
Increases for tax positions for prior years		167
Decreases for tax positions for prior years		(61	)
Increases for tax positions for current year		-
Settlements		-
Lapse of statute of limitations		-
Gross unrecognized tax benefits at December 31, 2011		1,056
Increases for tax positions for prior years		25
Decreases for tax positions for prior years		(65	)
Increases for tax positions for current year		-
Settlements		-
Lapse of statute of limitations		-
Gross unrecognized tax benefits at December 31, 2012		1,016
Increases for tax positions for prior years		165
Decreases for tax positions for prior years		-
Increases for tax positions for current year		15
Settlements		-
Lapse of statute of limitations		(75	)
Gross unrecognized tax benefits at December 31, 2013	$	1,121

Restructuring (Tables)

12 Months Ended

Dec. 31, 2013

Restructuring [Abstract]

Costs of the restructuring

	Incurred during
	the year ended
(in thousands)	December 31, 2013
Termination benefits	$	2,114
Contract termination costs		431
Other costs		261
Total	$	2,806

Summary of the activity for liabilities related to EPDU restructuring

The following is a summary of the activity for the liabilities related to the EPDU restructuring:

				Contract
	Termination			Termination			Other
(in thousands)	Benefits			Costs			Costs			Total
Balance at December 31, 2012	$	-			-		$	-		$	-
Expenses incurred		2,114			431			134			2,679
Amount paid		(1,660	)		(431	)		(134	)		(2,225	)
Other adjustments		-			-			-			-
Balance at December 31, 2013	$	454		$	-			-		$	454

Leases (Tables)

12 Months Ended

Dec. 31, 2013

Leases [Abstract]

Future Minimum Lease Payments under Operating Lease Obligations

Future minimum lease payments under operating lease obligations as of December 31, 2013 were as follows:

(in thousands)
2014		3,151
2015		1,981
2016		1,217
2017		-
Total minimum lease payments		6,349
Minimum lease receipts		(5,938	)

Total net minimum lease payments	$	411

Earnings per share (Tables)

12 Months Ended

Dec. 31, 2013

Earnings per share [Abstract]

Summary of basic and diluted net income per share

The following table presents the calculation of basic and diluted net income per share:

	Year Ended December 31,
(in thousands, except share and per share data)	2013		2012		2011
Numerator:
Net income	$	31,135	$	23,524	$	23,019

Denominator:
Weighted-average number of shares—basic		36,201,283		36,080,495		35,658,907
Dilutive securities—equity awards		546,273		340,167		547,145
Weighted-average number of shares—diluted		36,747,556		36,420,662		36,206,052

Earnings per share-basic	$	0.86	$	0.65	$	0.65
Earnings per share-diluted	$	0.85	$	0.65	$	0.64

Segment information (Tables)

12 Months Ended

Dec. 31, 2013

Segment information [Abstract]

Segment information

	Reportable Segments
(in thousands)	Biodefense		Biosciences			All Other			Total
Year Ended December 31, 2013
External revenue	$	311,564	$	1,181		$	-		$	312,745
Intersegment revenue (expense)		-		-			-			-
Research and development		62,663		50,652			6,618			119,933
Interest income		-		-			139			139
Interest expense		-		-			-			-
Depreciation and amortization		17,534		1,238			186			18,958
Net income (loss)		87,289		(50,925	)		(5,229	)		31,135
Intangible assets		30,148		-			-			30,148
In-process research and development assets		-		41,800			-			41,800
Goodwill		8,452		5,502						13,954
Total assets		331,827		98,510			196,293			626,630
Expenditures for long-lived assets		30,700		1,343			9,978			42,021
Year Ended December 31, 2012
External revenue	$	276,469	$	5,419		$	-		$	281,888
Intersegment revenue (expense)		-		-			-			-
Research and development		68,579		44,588			7,059			120,226
Interest income		-		-			134			134
Interest expense		-		-			(6	)		(6	)
Depreciation and amortization		8,951		2,147			99			11,197
Net income (loss)		94,865		(63,928	)		(7,413	)		23,524
In-process research and development assets		-		41,800			-			41,800
Goodwill		-		5,502			-			5,502
Total assets		354,010		56,148			154,072			564,230
Expenditures for long-lived assets		52,957		810			78			53,845
Year Ended December 31, 2011
External revenue	$	251,037	$	22,347		$	-		$	273,384
Intersegment revenue (expense)		-		-			-			-
Research and development		57,833		61,566			5,433			124,832
Interest income		-		-			105			105
Interest expense		-		-			-			-
Depreciation and amortization		6,213		3,070			72			9,355
Net income (loss)		86,836		(56,438	)		(7,379	)		23,019
In-process research and development assets		-		51,400			-			51,400
Goodwill		-		5,502			-			5,502
Total assets		290,302		92,321			164,241			546,864
Expenditures for long-lived assets		52,326		1,608			92			54,026

Quarterly financial data (unaudited) (Tables)

12 Months Ended

Dec. 31, 2013

Quarterly financial data (unaudited) [Abstract]

Quarterly financial information

Quarterly financial information for the years ended December 31, 2013 and 2012 is presented in the following tables:

	Three months ended
(in thousands)	March 31,			June 30,		September 30,		December 31,
Fiscal year 2013
Revenue	$	43,100		$	82,436	$	89,102	$	98,107
Income (loss) from operations		(13,350	)		14,712		18,147		23,293
Net income (loss)		(8,062	)		10,484		13,491		15,222
Net income (loss) per share, basic		(0.22	)		0.29		0.37		0.42
Net income (loss) per share, diluted		(0.22	)		0.29		0.36		0.41
Fiscal year 2012
Revenue	$	50,311		$	70,379	$	66,592	$	94,606
Income (loss) from operations		(12,538	)		8,653		9,817		24,035
Net income (loss)		(6,829	)		7,632		6,617		16,104
Net income (loss) per share, basic		(0.19	)		0.21		0.18		0.45
Net income (loss) per share, diluted		(0.19	)		0.21		0.18		0.44

Subsequent events (Tables) - Cangene [Member]

12 Months Ended

Dec. 31, 2013

Business Acquisition [Line Items]

Estimated Purchase Price

(in thousands)	February 21, 2014


Estimated fair value of tangible assets acquired and liabilities assumed:
Acquired tangible assets (i)	$	202,500
Assumed tangible liabilities		(38,300	)
Total estimated fair value of tangible assets acquired and liabilities assumed		164,200

Identified intangible assets		52,500
Deferred tax liability associated with identified intangible assets		(3,000	)
		49,500

Goodwill		8,300

Total preliminary estimated purchase price	$	222,000

(i)

Intangible Assets Acquired

The table below summarizes the preliminary estimated fair value of intangible assets acquired and the estimated amortization periods:

			Amortization
			Period
($ in thousands)	Amount		in years


Corporate trade name	$	2,600		5.0
Marketed products		5,100		15.0
Licensed products		1,900		3.0
Biodefense		34,400		15.0
Contract manufacturing		8,500		15.0

Total identified intangible assets	$	52,500

Pro Forma Results

	December 31,
(in thousands, except per share data)	2013		2012
Pro forma revenue	$	440,320	$	400,269
Pro forma net income	$	13,914	$	2,171

Nature of the business and organization (Details)	Dec. 31, 2013 a
Nature of the business and organization [Abstract]
Area of land in Lansing, Michigan (in acres)	12.5

Summary of significant accounting policies (Details) Dose in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2013 USD ($) Dose Plan shares	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Unbilled accounts receivable \| $	$ 60,587	$ 96,043
Revenue recognition [Abstract]
Number of doses of BioThrax to be supplied under contract \| Dose	44,750
Period of contractual agreement	5 years
Percentage of total spending in collaboration used to determine the receivable, revenue, payable and expense during period (in hundredths)	50.00%
Capitalized interest [Abstract]
Interest costs incurred \| $	$ 2,000	2,200	$ 1,700
Interest costs capitalized \| $	$ 2,000	$ 2,200	$ 1,700
Stock Options [Member]
Assumptions used in valuing the stock options granted [Abstract]
Expected dividend yield (in hundredths)	0.00%	0.00%	0.00%
Expected volatility (in hundredths)			60.00%
Risk-free interest rate, minimum (in hundredths)	0.32%	0.36%	0.35%
Risk-free interest rate, maximum (in hundredths)	0.70%	0.54%	1.04%
Expected average life of options	4 years 4 months 24 days	3 years 4 months 24 days	3 years 4 months 24 days
Stock Options [Member] \| Minimum [Member]
Assumptions used in valuing the stock options granted [Abstract]
Expected volatility (in hundredths)	39.00%	41.00%
Stock Options [Member] \| Maximum [Member]
Assumptions used in valuing the stock options granted [Abstract]
Expected volatility (in hundredths)	49.00%	52.00%
Buildings [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	31 years
Buildings [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	39 years
Building Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years
Building Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	39 years
Furniture and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Furniture and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	15 years
Software [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	Lesser of 3-5 years or product life
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	Lesser of the asset life or lease term
2006 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in number of shares of common stock available for issuance (in shares) \| shares	2,500,000
2006 Plan [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock authorized for issuance under the plan (in shares) \| shares	11,178,826
Common stock available for future awards (in shares) \| shares	2,387,463
Contractual life of awards	10 years
Exercise period of options, maximum	10 years
2006 Plan [Member] \| Stock Options [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of option as percentage of fair market value at grant date, minimum (in hundredths)	100.00%
2006 Plan [Member] \| Stock Options [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares that may be granted per year to a single participant (in shares) \| shares	287,700
2006 Plan [Member] \| Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock unit conversion ratio	1.86
Emergent Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock based employee compensation plans \| Plan	2
Revenues [Member] \| Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk percentage (in hundredths)	95.50%	97.90%	91.30%
Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk percentage (in hundredths)	96.20%	99.90%
Unbilled [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Unbilled accounts receivable \| $	$ 14,830	$ 19,888

Acquisition of Healthcare Protective Products Division (Details) - USD ($)		12 Months Ended
	Aug. 01, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Purchase Price Allocation [Abstract]
Goodwill		$ 13,954,000	$ 5,502,000	$ 5,502,000
HPPD [Member]
Purchase Price [Abstract]
Amount of cash paid to Bracco Diagnostics, Inc.	$ 25,873,000
Fair value of contingent purchase consideration	16,232,000
Total estimated purchase price	42,105,000
Purchase Price Allocation [Abstract]
Acquired intangible assets	32,099,000
Goodwill	8,452,000
Acquired equipment	1,543,000
Other	$ 11,000
Weighted average amortization period of intangible assets		89 months
Intangible Assets [Abstract]
Cost basis, beginning balance		$ 0
Additions		32,099,000
Cost basis, ending balance		32,099,000
Accumulated amortization, beginning balance		0
Amortization		(1,951,000)
Accumulated amortization, ending balance		(1,951,000)
Net book value at December 31, 2013		30,148,000
Future Amortization Expense [Abstract]
2014		4,737,000
2015		4,737,000
2016		4,255,000
2017		3,587,000
2018 and beyond		12,832,000
Total remaining amortization		30,148,000
Revenue included in statement of operations		11,200,000
Net income included in statement of operations		1,900,000
Acquisition transaction costs		600,000
HPPD [Member] \| RSDL [Member]
Purchase Price Allocation [Abstract]
Amortization period of intangible assets	8 years
Intangible Assets [Abstract]
Cost basis, beginning balance		0
Additions		28,621,000
Cost basis, ending balance		28,621,000
Accumulated amortization, beginning balance		0
Amortization		(1,468,000)
Accumulated amortization, ending balance		(1,468,000)
Net book value at December 31, 2013		27,153,000
Future Amortization Expense [Abstract]
Total remaining amortization		27,153,000
HPPD [Member] \| Manufacturing Agreement [Member]
Purchase Price Allocation [Abstract]
Amortization period of intangible assets	3 years
Intangible Assets [Abstract]
Cost basis, beginning balance		0
Additions		3,478,000
Cost basis, ending balance		3,478,000
Accumulated amortization, beginning balance		0
Amortization		(483,000)
Accumulated amortization, ending balance		(483,000)
Net book value at December 31, 2013		2,995,000
Future Amortization Expense [Abstract]
Total remaining amortization		$ 2,995,000
HPPD [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Contingent consideration, percentage of RSDL net sales (in hundredths)	5.00%
HPPD [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Contingent consideration, percentage of RSDL net sales (in hundredths)	10.00%

Fair value measurements (Details) - USD ($)

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Liabilities:

Fair value adjustment for contingent obligations

$ 735,000

$ (3,000,000)

$ 221,000

Payment of contingent obligations

1,700,000

10,000,000

Unobservable Input Reconciliation [Roll Forward]

Balance, beginning of period

4,753,000

Expense (income) included in earnings

735,000

(3,005,000)

Settlements

(348,000)

(1,748,000)

Purchases, sales and issuances

16,232,000

Transfers in/(out) of Level 3

Balance, end of period

16,619,000

$ 4,753,000

Fair Value, Measurements, Recurring [Member]

Assets:

Investment in money market funds

^[1]

37,701,000

42,720,000

Total assets

37,701,000

42,720,000

Liabilities:

Contingent price consideration

16,619,000

Total liabilities

16,619,000

Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]

Assets:

Investment in money market funds

^[1]

37,701,000

42,720,000

Total assets

37,701,000

42,720,000

Liabilities:

Contingent price consideration

Total liabilities

Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]

Assets:

Investment in money market funds

^[1]

Total assets

Liabilities:

Contingent price consideration

Total liabilities

Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]

Assets:

Investment in money market funds

^[1]

Total assets

$ 0

Liabilities:

Contingent price consideration

16,619,000

Total liabilities

$ 16,619,000

[1]	Included in cash and cash equivalents in accompanying consolidated balance sheets.

Accounts receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 60,587	$ 96,043
Billed [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	45,757	76,155
Unbilled [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 14,830	$ 19,888

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012
Inventories [Abstract]
Raw materials and supplies	$ 2,656	$ 2,733
Work-in-process	9,819	9,813
Finished goods	2,168	2,615
Total inventories	$ 14,643	$ 15,161

Property, plant and equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 321,611	$ 284,707
Less: Accumulated depreciation and amortization	(57,371)	(42,943)
Total Property, plant and equipment, net	264,240	241,764
Impairment related to equipment	1,200
Depreciation and amortization expense	18,958	11,197	$ 9,355
Land and improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	10,605	4,839
Buildings, building improvements and leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	83,823	66,953
Furniture and equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	107,006	91,772
Software [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	21,832	15,691
Construction-in-progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 98,345	$ 105,452

In-process research and development and goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2011
Segment Reporting Information [Line Items]
Goodwill	$ 5,502	$ 13,954	$ 5,502
Impairment of IPR&D assets	9,600
Biosciences [Member]
Segment Reporting Information [Line Items]
Goodwill	5,502	5,502	5,502
Biodefense [Member]
Segment Reporting Information [Line Items]
Goodwill	$ 0	$ 8,452	$ 0

Assets held for sale (Details) $ in Millions	12 Months Ended
Assets held for sale (Details) $ in Millions	Dec. 31, 2012 USD ($) Building
Assets held for sale [Abstract]
Number of buildings held for sale \| Building	2
Sales price of asset held for sale \| $	$ 12.2

Long-term debt (Details) $ / shares in Units, $ in Thousands	1 Months Ended		12 Months Ended
	Jan. 29, 2014 USD ($) shares $ / shares	Oct. 31, 2009	Dec. 31, 2013 USD ($) Institution	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 11, 2013 USD ($)	Dec. 31, 2009 USD ($)
Long-Term Debt [Line Items]
Long-term Debt, Total			$ 62,000	$ 62,774
Less current portion of long-term indebtedness			0	(4,470)
Noncurrent portion of long-term indebtedness			62,000	58,304
Payments on borrowings on long-term indebtedness			62,774	10,227	$ 15,494
Long-term Debt, Fiscal Year Maturity [Abstract]
2014			0
2015			0
2016			0
2017			0
2018 and thereafter			62,000
Long-term Debt, Total			62,000	62,774
Construction Loan [Member]
Long-Term Debt [Line Items]
Long-term Debt, Total			0	29,375
Long-term Debt, Fiscal Year Maturity [Abstract]
Long-term Debt, Total			0	$ 29,375
Construction Loan [Member] \| PNC Bank [Member]
Long-Term Debt [Line Items]
Interest rate, stated percentage (in hundredths)				3.00%
Debt instrument, type of variable interest rate				one month LIBOR
Maximum borrowing capacity				$ 30,000
Loan advance expiration date				Jul. 31, 2012
Equipment Loan [Member]
Long-Term Debt [Line Items]
Long-term Debt, Total			0	$ 11,068
Long-term Debt, Fiscal Year Maturity [Abstract]
Long-term Debt, Total			0	$ 11,068
Equipment Loan [Member] \| PNC Bank [Member]
Long-Term Debt [Line Items]
Interest rate, stated percentage (in hundredths)				3.00%
Debt instrument, type of variable interest rate				one month LIBOR
Maximum borrowing capacity				$ 12,000
Loan advance expiration date				Dec. 31, 2012
Term Loan December 2009 [Member]
Long-Term Debt [Line Items]
Long-term Debt, Total			0	$ 18,200
Long-term Debt, Fiscal Year Maturity [Abstract]
Long-term Debt, Total			0	$ 18,200
Term Loan December 2009 [Member] \| HSBC Bank [Member]
Long-Term Debt [Line Items]
Interest rate, stated percentage (in hundredths)				3.25%
Debt instrument, type of variable interest rate				three month LIBOR
Maturity date				Dec. 31, 2014
Face amount of debt instrument				$ 22,800
Prior Term Loan Replaced in December 2009 [Member] \| HSBC Bank [Member]
Long-Term Debt [Line Items]
Maximum borrowing capacity							$ 30,000
Term Loan November 2009 [Member]
Long-Term Debt [Line Items]
Long-term Debt, Total			0	4,131
Long-term Debt, Fiscal Year Maturity [Abstract]
Long-term Debt, Total			$ 0	4,131
Term Loan November 2009 [Member] \| HSBC Bank [Member]
Long-Term Debt [Line Items]
Interest rate, stated percentage (in hundredths)		3.25%
Debt instrument, type of variable interest rate		three month LIBOR
BAML Revolving Credit Facility [Member]
Long-Term Debt [Line Items]
Long-term Debt, Total				0
Interest rate, stated percentage (in hundredths)			2.75%
Debt instrument, type of variable interest rate			one month LIBOR
Maximum borrowing capacity			$ 100,000
Long-term Debt, Fiscal Year Maturity [Abstract]
Long-term Debt, Total				$ 0
BAML Revolving Credit Facility [Member] \| Subsequent Event [Member]
Long-Term Debt [Line Items]
Payments on borrowings on long-term indebtedness	$ 62,000
Credit Agreement [Member]
Long-Term Debt [Line Items]
Number of lending institutions \| Institution			3
Proceeds from borrowings on long-term indebtedness			$ 62,000
Deferred financing costs			$ 3,400			$ 3,500
Debt covenant, consolidated debt service coverage ratio, minimum			2.50
Debt covenant, leverage ratio, maximum			3.50
Debt Instrument, covenant, senior leverage ratio, maximum			2.00
Debt covenant, minimum cash and liquid investments balance			$ 50,000
Term Loan Facility [Member]
Long-Term Debt [Line Items]
Maturity date			Mar. 31, 2014
2.875% Convertible Senior Notes Due 2021 [Member] \| Subsequent Event [Member]
Long-Term Debt [Line Items]
Interest rate, stated percentage (in hundredths)	2.875%
Maturity date	Jan. 15, 2021
Face amount of debt instrument	$ 250,000
Conversion rate of notes per $1,000 principal amount (in shares) \| shares	30.8821
Conversion price per share (in dollars per share) \| $ / shares	$ 32.38
BAML Term Loan Member
Long-Term Debt [Line Items]
Maturity date			Dec. 11, 2018
Maximum borrowing capacity			$ 125,000

Stockholders' equity (Details) - USD ($)	12 Months Ended
Stockholders' equity (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012
Preferred stock
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, voting rights	1
Treasury Stock [Abstract]
Stock repurchased during period, value	$ 213,000	$ 5,906,000
Senior Managment [Member]
Treasury Stock [Abstract]
Stock repurchased as part of stock swap (in shares)	14,472
Stock repurchased as part of stock swap, value	$ 287,000
Stock Repurchase Plan of 2012 [Member]
Treasury Stock [Abstract]
Stock Repurchase Program, Authorized Amount	$ 35,000,000
Stock repurchased during period (in shares)	398,481
Stock repurchased during period, value	$ 5,800,000

Stockholders' equity, Share-based Compensation Arrangements by Share-based Payment Award (Details)	12 Months Ended
	Dec. 31, 2013 USD ($) Plan $ / shares shares	Dec. 31, 2012 USD ($) $ / shares shares	Dec. 31, 2011 USD ($) $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense \| $	$ 11,238,000	$ 11,115,000	$ 10,739,000
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense \| $	11,110,000	11,115,000	$ 10,739,000
Stock Options [Member]
Aggregate Intrinsic Value [Abstract]
Outstanding, beginning of period \| $	4,801,378
Exercisable, beginning of period \| $	4,476,830
Outstanding, end of period \| $	23,148,738	4,801,378
Exercisable, end of period \| $	12,685,394	$ 4,476,830
Options expected to vest, end of period \| $	$ 7,820,256
Aggregate intrinsic value [Abstract]
Weighted average remaining contractual term of options outstanding	4 years 1 month 6 days	4 years 2 months 12 days
Weighted average remaining contractual term of options exercisable	3 years 4 months 24 days	3 years 6 months
Weighted average grant date fair value of options granted (in dollars per share) \| $ / shares	$ 5.38	$ 5.16	$ 10.09
Total intrinsic value of options exercised \| $	$ 6,900,000	$ 589,000	$ 10,200,000
Total fair value of awards vested \| $	$ 9,100,000	$ 10,300,000	7,900,000
2006 Plan [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock authorized for issuance under the plan (in shares)	11,178,826
Options outstanding [Roll Forward]
Outstanding, beginning of period (in shares)	3,549,842
Exercisable, beginning of period (in shares)	2,144,732
Granted (in shares)	993,544
Exercised (in shares)	(481,549)
Forfeited (in shares)	(419,742)
Outstanding, end of period (in shares)	3,642,095	3,549,842
Exercisable, end of period (in shares)	2,074,772	2,144,732
Options expected to vest, end of period (in shares)	1,171,171
Weighted-Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share) \| $ / shares	$ 17.08
Exercisable, beginning of period (in dollars per share) \| $ / shares	16.25
Granted (in dollars per share) \| $ / shares	15.21
Exercised (in dollars per share) \| $ / shares	12.61
Forfeited (in dollars per share) \| $ / shares	18.34
Outstanding, end of period (in dollars per share) \| $ / shares	17.01	$ 17.08
Exercisable, end of period (in dollars per share) \| $ / shares	17.44	$ 16.25
Options expected to vest, end of period (in dollars per share) \| $ / shares	$ 16.44
2006 Plan [Member] \| Stock Options [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares that may be granted per year to a single participant (in shares)	287,700
2006 Plan [Member] \| Restricted Stock Units (RSUs) [Member]
Restricted stock unit award activity [Roll Forward]
Outstanding, beginning of period (in shares)	715,276
Granted (in shares)	496,771
Vested (in shares)	(337,498)
Forfeited (in shares)	(80,873)
Outstanding, end of period (in shares)	793,676	715,276
Weighted-Average Grant Price [Roll Forward]
Outstanding, beginning of period (in dollars per share) \| $ / shares	$ 18.41
Granted (in dollars per share) \| $ / shares	15.21
Vested (in dollars per share) \| $ / shares	14.91
Forfeited (in dollars per share) \| $ / shares	16.72
Outstanding, end of period (in dollars per share) \| $ / shares	$ 16.52	$ 18.41
Aggregate intrinsic value [Abstract]
Outstanding, beginning of period \| $	$ 11,473,027
Outstanding, end of period \| $	$ 18,246,611	$ 11,473,027
2004 Plan [Member] \| Stock Options [Member]
Options outstanding [Roll Forward]
Outstanding, beginning of period (in shares)	53,156
Exercisable, beginning of period (in shares)	53,156
Granted (in shares)	0
Exercised (in shares)	0
Forfeited (in shares)	0
Outstanding, end of period (in shares)	53,156	53,156
Exercisable, end of period (in shares)	53,156	53,156
Options expected to vest, end of period (in shares)	0
Weighted-Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share) \| $ / shares	$ 8.86
Exercisable, beginning of period (in dollars per share) \| $ / shares	8.86
Granted (in dollars per share) \| $ / shares	0
Exercised (in dollars per share) \| $ / shares	0
Forfeited (in dollars per share) \| $ / shares	0
Outstanding, end of period (in dollars per share) \| $ / shares	8.86	$ 8.86
Exercisable, end of period (in dollars per share) \| $ / shares	8.86	$ 8.86
Options expected to vest, end of period (in dollars per share) \| $ / shares	$ 0
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Threshold limit for common stock ownership to be ineligible to participate in ESPP (in hundredths)	5.00%
Common stock authorized for issuance under the plan (in shares)	1,000,000
Number of plan periods \| Plan	2
Discount from market price (in hundredths)	15.00%
Maximum number of shares that may be granted per year to a single participant (in shares)	800
Stock-based compensation expense \| $	$ 128,000
Employee Stock Purchase Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee subscription rate (in hundredths)	1.00%
Employee Stock Purchase Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee subscription rate (in hundredths)	10.00%
Cost of Product Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense \| $	$ 575,000	$ 513,000	466,000
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense \| $	3,283,000	3,451,000	3,203,000
Selling, General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense \| $	$ 7,252,000	$ 7,151,000	$ 7,070,000

Income taxes (Details) - USD ($) $ in Thousands	12 Months Ended
Income taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current
Federal	$ (878)	$ 11,481	$ (3,795)
State	(173)	(1,045)	(1,110)
International	300	103	74
Total current	(751)	10,539	(4,831)
Deferred
Federal	12,679	3,758	19,055
State	1,028	(375)	1,606
International	152	0	0
Total deferred	13,859	3,383	20,661
Total provision for income taxes	13,108	13,922	15,830
Net deferred tax asset [Abstract]
Net operating loss carryforward	23,256	26,102
Research and development carryforward	7,395	3,556
Stock compensation	6,378	5,289
Foreign deferrals	64,090	64,009
Deferred revenue	0	0
Other	4,522	9,005
Deferred tax asset	105,641	107,961
Fixed assets	(32,588)	(22,040)
Other	(5,714)	(6,158)
Deferred tax liability	(38,302)	(28,198)
Valuation allowance	(68,846)	(67,412)
Net deferred tax asset	(1,507)	12,351
Income tax reconciliation [Abstract]
US	52,749	52,391	66,756
International	(8,506)	(14,945)	(27,907)
Earnings before taxes on income	44,243	37,446	38,849
Federal tax at statutory rates	15,485	13,106	13,597
State taxes, net of federal benefit	538	(2,079)	46
Impact of foreign operations	(1,116)	(3,604)	(2,371)
Change in valuation allowance	1,434	4,629	3,193
Effect of foreign rates	0	(22)	(12)
Tax credits	(5,918)	(2,904)	(1,405)
Other differences	(227)	139	556
Permanent differences	2,912	4,657	2,226
Total provision for income taxes	$ 13,108	$ 13,922	$ 15,830
Effective annual tax rate (in hundredths)	30.00%	37.00%	41.00%
Research and Development Tax Credit [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforward, amount	$ 7,400
Tax credit carryforwards, expiration date	Dec. 31, 2023
U.S. Federal Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 34,100
Operating loss carryforwards, expiration year	Dec. 31, 2026
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 211,500
Operating loss carryforwards, expiration year	Dec. 31, 2018
Foreign Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 227,600
Period of change in the nature or conduct of business following change in ownership	3 years

Income taxes, Income Tax Contingency (Details) - USD ($)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Income Tax Contingency [Line Items]
Accrued interest and penalties related to unrecognized tax benefits	$ 15,000	$ 25,000
Unrecognized tax benefits, current	132,000	153,000
Unrecognized tax benefits, noncurrent	991,000	863,000
Estimated unrecognized tax benefits expected to be reversed within next twelve months	152,000	75,000
Gross unrecognized tax benefits activity [Roll Forward]
Gross unrecognized tax benefits, beginning balance	1,016,000	1,056,000	$ 950,000
Increases for tax positions for prior years	165,000	25,000	167,000
Decreases for tax positions for prior years	0	(65,000)	(61,000)
Increases for tax positions for current year	15,000	0	0
Settlements	0	0	0
Lapse of statute of limitations	(75,000)	0	0
Gross unrecognized tax benefits, ending balance	$ 1,121,000	$ 1,016,000	$ 1,056,000
U.S. Federal Tax Authority [Member] \| Minimum [Member]
Gross unrecognized tax benefits activity [Roll Forward]
Open tax year	2010
Federal income tax year selected for audit	2008
U.S. Federal Tax Authority [Member] \| Maximum [Member]
Gross unrecognized tax benefits activity [Roll Forward]
Open tax year	2012
Federal income tax year selected for audit	2010
United Kingdom Tax Authority [Member] \| Minimum [Member]
Gross unrecognized tax benefits activity [Roll Forward]
Open tax year	2006
United Kingdom Tax Authority [Member] \| Maximum [Member]
Gross unrecognized tax benefits activity [Roll Forward]
Open tax year	2013

Variable interest entities (Details) - USD ($)	12 Months Ended
Variable interest entities (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Selling, General and Administrative Expenses [Member] \| Biosciences [Member]
Variable Interest Entity [Line Items]
Reclassified accumulated translation adjustments	$ 83,000
Oxford-Emergent Tuberculosis Consortium [Member]
Variable Interest Entity [Line Items]
Assets of variable interest entities included in consolidated balance sheet	305,000	$ 2,000,000
Liabilities of variable interest entities included in consolidated balance sheet	249,000	2,000,000
Net loss	(1,800,000)	(10,700,000)	$ (13,200,000)
Net losses of variable interest entities included in consolidated statement of operations	$ (910,000)	$ (5,400,000)	$ (6,700,000)

Collaboration Agreements (Details) - USD ($)	12 Months Ended
Collaboration Agreements (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Collaborative arrangements [Line Items]
Contracts and grants revenue	$ 54,823,000	$ 66,009,000	$ 70,975,000
Abbott Laboratories TRU016 [Member]
Collaborative arrangements [Line Items]
Contracts and grants revenue		2,700,000	17,700,000
Recognition of deferred revenue		1,400,000	10,500,000
Revenue related to achievement of a development milestone			6,000,000
Revenues related to collaborative research funding		1,400,000	1,200,000
Pfizer CD20 [Member]
Collaborative arrangements [Line Items]
Contracts and grants revenue		1,200,000	1,900,000
Recognition of deferred revenue		68,000	52,000
Revenues related to collaborative research funding		$ 1,100,000	$ 1,800,000

Restructuring (Details) $ in Thousands	12 Months Ended
Restructuring (Details) $ in Thousands	Dec. 31, 2013 USD ($) Employee
Restructuring Cost and Reserve [Line Items]
Headcount reduction \| Employee	14
Total incurred	$ 2,806
Summary of activity for liabilities [Roll Forward]
Beginning balance	0
Expenses incurred	2,679
Amount paid	(2,225)
Other adjustments	0
Ending balance	454
Restructuring expenses	2,679
EPDU Restructuring Plan [Member]
Summary of activity for liabilities [Roll Forward]
Beginning balance	0
Amount paid	(134)
Other adjustments	0
Ending balance	0
Termination benefits [Member]
Restructuring Cost and Reserve [Line Items]
Total incurred	2,114
Termination benefits [Member] \| EPDU Restructuring Plan [Member]
Summary of activity for liabilities [Roll Forward]
Beginning balance	0
Expenses incurred	2,114
Amount paid	(1,660)
Other adjustments	0
Ending balance	454
Restructuring expenses	2,114
Contract termination costs [Member]
Restructuring Cost and Reserve [Line Items]
Total incurred	431
Contract termination costs [Member] \| EPDU Restructuring Plan [Member]
Summary of activity for liabilities [Roll Forward]
Beginning balance	0
Expenses incurred	431
Amount paid	(431)
Other adjustments	0
Ending balance	0
Restructuring expenses	431
Other costs [Member]
Restructuring Cost and Reserve [Line Items]
Total incurred	261
Other costs [Member] \| EPDU Restructuring Plan [Member]
Summary of activity for liabilities [Roll Forward]
Expenses incurred	134
Restructuring expenses	$ 134

401(k) savings plan (Details) - USD ($) $ in Millions	12 Months Ended
401(k) savings plan (Details) - USD ($) $ in Millions	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
401(k) savings plan [Abstract]
Matching of qualified deferrals by employer, maximum (in hundredths)	50.00%
Percentage of employee's gross salary subject to employer's matching contribution (in hundredths)	6.00%
Matching contributions made by employer	$ 2.0	$ 1.9	$ 1.8

Leases (Details) - USD ($)	12 Months Ended
Leases (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Operating Leased Assets [Line Items]
Total lease expense	$ 3,900,000	$ 3,600,000	$ 3,800,000
Rental income	446,000
Future minimum lease payments under operating lease
2014	3,151,000
2015	1,981,000
2016	1,217,000
2017	0
Total minimum lease payments	6,349,000
Minimum lease receipts	(5,938,000)
Total net minimum lease payments	$ 411,000
Office and laboratory space - Germany [Member]
Operating Leased Assets [Line Items]
Operating lease expiration date	Jun. 30, 2015
Office space - England [Member]
Operating Leased Assets [Line Items]
Operating lease expiration date	Nov. 30, 2016
Office and laboratory space - Maryland [Member]
Operating Leased Assets [Line Items]
Operating lease expiration date	Dec. 31, 2016
Annual escalation percentage (in hundredths)	3.00%
Office and laboratory space - Washington [Member]
Operating Leased Assets [Line Items]
Operating lease expiration date	Apr. 30, 2015

Business interruption insurance recovery (Details) $ in Millions	12 Months Ended
	Dec. 31, 2012 USD ($)
Business interruption insurance recovery [Abstract]
Business interruption insurance revenue	$ 1.7

Related party transactions (Details) - USD ($)	12 Months Ended
Related party transactions (Details) - USD ($)	Dec. 31, 2013	Dec. 31, 2011
Saudi Arabia [Member]
Related Party Transaction [Line Items]
Percentage of net sales of biodefense products subject to payment to related party (in hundredths)	17.50%
Qatar [Member]
Related Party Transaction [Line Items]
Percentage of net sales of biodefense products subject to payment to related party (in hundredths)	15.00%
United Arab Emirates [Member]
Related Party Transaction [Line Items]
Percentage of net sales of biodefense products subject to payment to related party (in hundredths)	15.00%
Family Members of Executive Chairman [Member]
Related Party Transaction [Line Items]
Costs incurred from services rendered under marketing/consulting agreement		$ 35,000
Member of Board of Directors [Member]
Related Party Transaction [Line Items]
Costs incurred from services rendered under marketing/consulting agreement		$ 225,000

Earnings per share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Numerator:
Net income	$ 15,222	$ 13,491	$ 10,484	$ (8,062)	$ 16,104	$ 6,617	$ 7,632	$ (6,829)	$ 31,135	$ 23,524	$ 23,019
Denominator:
Weighted-average number of shares-basic (in shares)									36,201,283	36,080,495	35,658,907
Dilutive securities-equity awards (in shares)									546,273	340,167	547,145
Weighted-average number of shares-diluted (in shares)									36,747,556	36,420,662	36,206,052
Earnings per share-basic (in dollars per share)	$ 0.42	$ 0.37	$ 0.29	$ (0.22)	$ 0.45	$ 0.18	$ 0.21	$ (0.19)	$ 0.86	$ 0.65	$ 0.65
Earnings per share-diluted (in dollars per share)	$ 0.41	$ 0.36	$ 0.29	$ (0.22)	$ 0.44	$ 0.18	$ 0.21	$ (0.19)	$ 0.85	$ 0.65	$ 0.64
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares excluded from calculation (in shares)									1,500,000	2,900,000	746,000

Segment information (Details) $ in Thousands	3 Months Ended								12 Months Ended
Segment information (Details) $ in Thousands	Dec. 31, 2013 USD ($)	Sep. 30, 2013 USD ($)	Jun. 30, 2013 USD ($)	Mar. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Sep. 30, 2012 USD ($)	Jun. 30, 2012 USD ($)	Mar. 31, 2012 USD ($)	Dec. 31, 2013 USD ($) Segment BusinessUnit	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)
Segment Reporting Information [Line Items]
Number of business segments \| Segment									2
Number of business units \| BusinessUnit									2
Revenue									$ 312,745	$ 281,888	$ 273,384
Research and development									119,933	120,226	124,832
Interest revenue									139	134	105
Interest expense									0	(6)	0
Depreciation and amortization									18,958	11,197	9,355
Net income (loss)	$ 15,222	$ 13,491	$ 10,484	$ (8,062)	$ 16,104	$ 6,617	$ 7,632	$ (6,829)	31,135	23,524	23,019
Intangible assets	30,148				0				30,148	0
In-process research and development assets	41,800				41,800				41,800	41,800	51,400
Goodwill	13,954				5,502				13,954	5,502	5,502
Total assets	626,630				564,230				626,630	564,230	546,864
Expenditures for long-lived assets									42,021	53,845	54,026
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenue									0	0	0
Biodefense [Member]
Segment Reporting Information [Line Items]
Revenue									311,564	276,469	251,037
Research and development									62,663	68,579	57,833
Interest revenue									0	0	0
Interest expense									0	0	0
Depreciation and amortization									17,534	8,951	6,213
Net income (loss)									87,289	94,865	86,836
Intangible assets	30,148								30,148
In-process research and development assets	0				0				0	0	0
Goodwill	8,452				0				8,452	0	0
Total assets	331,827				354,010				331,827	354,010	290,302
Expenditures for long-lived assets									30,700	52,957	52,326
Biodefense [Member] \| Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenue									0	0	0
Biosciences [Member]
Segment Reporting Information [Line Items]
Revenue									1,181	5,419	22,347
Research and development									50,652	44,588	61,566
Interest revenue									0	0	0
Interest expense									0	0	0
Depreciation and amortization									1,238	2,147	3,070
Net income (loss)									(50,925)	(63,928)	(56,438)
Intangible assets	0								0
In-process research and development assets	41,800				41,800				41,800	41,800	51,400
Goodwill	5,502				5,502				5,502	5,502	5,502
Total assets	98,510				56,148				98,510	56,148	92,321
Expenditures for long-lived assets									1,343	810	1,608
Biosciences [Member] \| Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenue									0	0	0
All Other [Member]
Segment Reporting Information [Line Items]
Revenue									0	0	0
Research and development									6,618	7,059	5,433
Interest revenue									139	134	105
Interest expense									0	(6)	0
Depreciation and amortization									186	99	72
Net income (loss)									(5,229)	(7,413)	(7,379)
Intangible assets	0								0
In-process research and development assets	0				0				0	0	0
Goodwill					0					0	0
Total assets	$ 196,293				$ 154,072				196,293	154,072	164,241
Expenditures for long-lived assets									9,978	78	92
All Other [Member] \| Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenue									$ 0	$ 0	$ 0

Quarterly financial data (unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Quarterly financial data (unaudited) [Abstract]
Revenue	$ 98,107	$ 89,102	$ 82,436	$ 43,100	$ 94,606	$ 66,592	$ 70,379	$ 50,311	$ 312,745	$ 281,888	$ 273,384
Income (loss) from operations	23,293	18,147	14,712	(13,350)	24,035	9,817	8,653	(12,538)	42,802	29,967	32,099
Net income (loss)	$ 15,222	$ 13,491	$ 10,484	$ (8,062)	$ 16,104	$ 6,617	$ 7,632	$ (6,829)	$ 31,135	$ 23,524	$ 23,019
Net income (loss) per share, basic (in dollars per share)	$ 0.42	$ 0.37	$ 0.29	$ (0.22)	$ 0.45	$ 0.18	$ 0.21	$ (0.19)	$ 0.86	$ 0.65	$ 0.65
Net income (loss) per share, diluted (in dollars per share)	$ 0.41	$ 0.36	$ 0.29	$ (0.22)	$ 0.44	$ 0.18	$ 0.21	$ (0.19)	$ 0.85	$ 0.65	$ 0.64